Patent Application
20150057246
The present invention relates to novel Silyl-Containing Heterocyclic Compounds, compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
Hepatitis C virus (HCV) is a major human pathogen. A substantial fraction of these HCV-infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma, which are often fatal. HCV is a (+)-sense single-stranded enveloped RNA virus that has been implicated as the major causative agent in non-A, non-B hepatitis (NANBH), particularly in blood-associated NANBH (BB-NANBH) (see, International Publication No. WO 89/04669 and European Patent Publication No. EP 381 216). NANBH is to be distinguished from other types of viral-induced liver disease, such as hepatitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as from other forms of liver disease such as alcoholism and primary biliar cirrhosis.
It is well-established that persistent infection of HCV is related to chronic hepatitis, and as such, inhibition of HCV replication is a viable strategy for the prevention of hepatocellular carcinoma. Current therapies for HCV infection include α-interferon monotherapy and combination therapy comprising α-interferon and ribavirin. These therapies have been shown to be effective in some patients with chronic HCV infection, but suffer from poor efficacy and unfavorable side-effects and there are currently efforts directed to the discovery of HCV replication inhibitors that are useful for the treatment and prevention of HCV related disorders.
Current research efforts directed toward the treatment of HCV includes the use of antisense oligonucleotides, free bile acids (such as ursodeoxycholic acid and chenodeoxycholic acid) and conjugated bile acids (such as tauroursodeoxycholic acid). Phosphonoformic acid esters have also been proposed as potentially useful for the treatment of various viral infections, including HCV. Vaccine development, however, has been hampered by the high degree of viral strain heterogeneity and immune evasion and the lack of protection against reinfection, even with the same inoculum.
In light of these treatment hurdles, the development of small-molecule inhibitors directed against specific viral targets has become a major focus of anti-HCV research. The determination of crystal structures for NS3 protease, NS3 RNA helicase, NS5A, and NS5B polymerase, with and without bound ligands, has provided important structural insights useful for the rational design of specific inhibitors.
Recent attention has been focused toward the identification of inhibitors of HCV NS5A. HCV NS5A is a 447 amino acid phosphoprotein which lacks a defined enzymatic function. It runs as 56 kd and 58 kd bands on gels depending on phosphorylation state (Tanji, et al. J. Virol. 69:3980-3986 (1995)). HCV NS5A resides in replication complex and may be responsible for the switch from replication of RNA to production of infectious virus (Huang, Y, et al., Virology 364:1-9 (2007)).
Multicyclic HCV NS5A inhibitors have been reported. See U.S. Patent Publication Nos. US20080311075, US20080044379, US20080050336, US20080044380, US20090202483 and US2009020478. HCV NS5A inhibitors having fused tricyclic moieties are disclosed in International Patent Publication Nos. WO 10/065,681, WO 10/065,668, and WO 10/065,674.
Other HCV NS5A inhibitors and their use for reducing viral load in HCV infected humans have been described in U.S. Patent Publication No. US20060276511.
In one aspect, the present invention provides Compounds of Formula (I)
or a pharmaceutically acceptable salt thereof,
wherein:
A is 4 to 7-membered monocyclic heterocycloalkyl, 7 to 11-membered bicyclic heterocycloalkyl or R15, wherein said 4 to 7-membered monocyclic heterocycloalkyl group or said 7 to 11-membered bicyclic heterocycloalkyl can be optionally and independently substituted on one or more ring nitrogen atoms with R4, and on one or more ring carbon atoms with R12, such that two R12 groups on the same ring carbon atom, together with the carbon atom to which they are attached, can join to form a spirocyclic 3 to 7-membered cycloalkyl group or a spirocyclic 4 to 7-membered heterocycloalkyl group;
B is a 5-membered monocyclic heteroarylene or 9-membered bicyclic heteroarylene, wherein said 5-membered monocyclic heteroarylene group and said 9-membered bicyclic heteroarylene group can be optionally and independently substituted on one or more ring nitrogen atoms with R6 and on one or more ring carbon atoms with R12;
C is a bond, phenylene, naphthylene, 5-membered monocyclic heteroarylene or 9-membered bicyclic heteroarylene, wherein said phenylene group, said naphthylene group, said 5-membered monocyclic heteroarylene group or said 9-membered bicyclic heteroarylene group can be optionally and independently substituted on one or more ring nitrogen atoms with R6 and on one or more ring carbon atoms with R12;
D is 4 to 7-membered monocyclic heterocycloalkyl, 7 to 11-membered bicyclic heterocycloalkyl or R15, wherein said 4 to 7-membered monocyclic heterocycloalkyl group or said 7 to 11-membered bicyclic heterocycloalkyl group can be optionally and independently substituted on one or more ring nitrogen atoms with R4, and on one or more ring carbon atoms with R12, such that two R12 groups on the same ring carbon atom, together with the carbon atom to which they are attached, can join to form a spirocyclic 3 to 7-membered cycloalkyl group or a spirocyclic 4 to 7-membered heterocycloalkyl group, such that at least one of A and D is R15;
each occurrence of R1 is independently C1-C6 alkyl, C1-C6 haloalkyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl or heteroaryl, wherein said 3- to 7-membered cycloalkyl group, said 4- to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally substituted with up to three groups, which can be the same or different, and are selected from C1-C6 alkyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl, heteroaryl, halo, C1-C6 haloalkyl, —Si(R13)3, —CN, —OR3, —N(R3)2, —C(O)R10, —C(O)OR3, —C(O)N(R3)2, —NHC(O)R10, —NHC(O)NHR3, —NHC(O)OR3, —OC(O)R10, —SR3 and —S(O)2R10;
each occurrence of R2 is independently H, C1-C6 alkyl, —C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, C1-C6 hydroxyalkyl, —OH, —O—(C1-C6 alkyl), halo, —CN, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)—(C1-C6 alkyl), —C(O)NH—(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, or —Si(R13)3;
each occurrence of R3 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, —C1-C6 alkylene-OC(O)(C1-C6 alkyl), C1-C6 hydroxyalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl wherein said 3- to 7-membered cycloalkyl group, said 4- to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to three groups independently selected from —OH, halo, C1-C6 alkyl, C1-C6 haloalkyl, —NH(C1-C6 alkyl) and —N(C1-C6 alkyl)2;
each occurrence of R4 is independently H, C1-C6 haloalkyl, —C(O)R1, —C(O)OR1, —C(O)CH(R7)NHC(O)OR1 or —C(O)—CH(R7)—N(R1)2;
each occurrence of R5 is independently H, —Si(R13)3, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl or heteroaryl;
each occurrence of R6 is independently H, C1-C6 alkyl, 3- to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl, wherein said 3- to 7-membered cycloalkyl group, said 4- to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to two R8 groups, and wherein two R6 groups that are attached to a common nitrogen atom, together with the nitrogen atom to which they are attached, can optionally join to form a 4- to 7-membered heterocycloalkyl group;
each occurrence of R7 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, benzyl, -alkylene-O—(C1-C6 alkyl), silylalkyl, 3- to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl or heteroaryl, wherein said benzyl group, said 3- to 7-membered cycloalkyl group, said 4- to 7-membered heterocycloalkyl group, said aryl group or said heteroaryl group can be optionally and independently substituted with up to three R8 groups;
each occurrence of R8 is independently H, C1-C6 alkyl, halo, —C1-C6 haloalkyl, C1-C6 hydroxyalkyl, —OH, —C(O)NH—(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —O—(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2 and —NHC(O)—(C1-C6 alkyl) or —Si(R13)3;
each occurrence of R10 is independently C1-C6 alkyl, C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl, or heteroaryl;
each occurrence of R12 is H, C1-C6 alkyl, C1-C6 haloalkyl, 3 to 7-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, aryl, heteroaryl, halo, —CN, —OR3, —N(R3)2, —C(O)R10, —C(O)OR3, —C(O)N(R3)2, —NHC(O)R10, —NHC(O)NHR3, —NHC(O)OR3, —OC(O)R10, —SR3, —S(O)2R10 or Si(R13)3 and wherein two R12 groups together with the carbon atom(s) to which they are attached, can optionally join to form a 5 to 7-membered cycloalkyl or 4- to 7-membered heterocycloalkyl ring;
each occurrence of R13 is independently selected from C1-C6 alkyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl, heteroaryl, C1-C6 haloalkyl, —CN and —OR3, wherein two R13 groups, together with the silicon atom to which they are attached, can optionally join to form a 4- to 7-membered silicon-containing heterocycloalkyl ring; and
each occurrence of R15 is independently a monocyclic 5- to 7-membered silylheterocycloalkyl ring or a bicyclic 7- to 11-membered bicyclic silylheterocycloalkyl ring wherein said silylheterocycloalkyl rings contains as heteroatom ring members:
The Compounds of Formula (I) (also referred to herein as the “Silyl-Containing Heterocyclic Compounds”) and pharmaceutically acceptable salts thereof can be useful, for example, for inhibiting HCV viral replication or replicon activity, and for treating or preventing HCV infection in a patient. Without being bound by any specific theory, it is believed that the Silyl-Containing Heterocyclic Compounds inhibit HCV viral replication by inhibiting HCV NS5A.
Accordingly, the present invention provides methods for treating or preventing HCV infection in a patient, comprising administering to the patient an effective amount of at least one Silyl-Containing Heterocyclic Compound.
The details of the invention are set forth in the accompanying detailed description below.
Although any methods and materials similar to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
The present invention relates to novel Silyl-Containing Heterocyclic Compounds, compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “hydroxyalkyl,” “haloalkyl,” “—O-alkyl,” etc. . . .
As used herein, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
A “patient” is a human or non-human mammal. In one embodiment, a patient is a human. In another embodiment, a patient is a chimpanzee.
The term “effective amount” as used herein, refers to an amount of Silyl-Containing Heterocyclic Compound and/or an additional therapeutic agent, or a composition thereof that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a patient suffering from a viral infection or virus-related disorder. In the combination therapies of the present invention, an effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.
The term “preventing,” as used herein with respect to an HCV viral infection or HCV-virus related disorder, refers to reducing the likelihood of HCV infection.
The term “alkyl,” as used herein, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond. An alkyl group may be straight or branched and contain from about 1 to about 20 carbon atoms. In one embodiment, an alkyl group contains from about 1 to about 12 carbon atoms. In different embodiments, an alkyl group contains from 1 to 6 carbon atoms (C1-C6 alkyl) or from about 1 to about 4 carbon atoms (C1-C4 alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. An alkyl group may be unsubstituted or substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, —O-alkyl, —O-aryl, -alkylene-O-alkyl, alkylthio, —NH2, —NH(alkyl), —N(alkyl)2, —NH(cycloalkyl), —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, —C(O)OH and —C(O)O—alkyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched. Unless otherwise indicated, an alkyl group is unsubstituted.
The term “alkenyl,” as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and having one of its hydrogen atoms replaced with a bond. An alkenyl group may be straight or branched and contain from about 2 to about 15 carbon atoms. In one embodiment, an alkenyl group contains from about 2 to about 12 carbon atoms. In another embodiment, an alkenyl group contains from about 2 to about 6 carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl. An alkenyl group may be unsubstituted or substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, —O-alkyl, —O-aryl, -alkylene-β-alkyl, alkylthio, —NH2, —NH(alkyl), —N(alkyl)2, —NH(cycloalkyl), —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, —C(O)OH and —C(O)O-alkyl. The term “C2-C6 alkenyl” refers to an alkenyl group having from 2 to 6 carbon atoms. Unless otherwise indicated, an alkenyl group is unsubstituted.
The term “alkynyl,” as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and having one of its hydrogen atoms replaced with a bond. An alkynyl group may be straight or branched and contain from about 2 to about 15 carbon atoms. In one embodiment, an alkynyl group contains from about 2 to about 12 carbon atoms. In another embodiment, an alkynyl group contains from about 2 to about 6 carbon atoms. Non-limiting examples of alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. An alkynyl group may be unsubstituted or substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, —O-alkyl, —O-aryl, -alkylene-O-alkyl, alkylthio, —NH2, —NH(alkyl), —N(alkyl)2, —NH(cycloalkyl), —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, —C(O)OH and —C(O)O-alkyl. The term “C2-C6 alkynyl” refers to an alkynyl group having from 2 to 6 carbon atoms. Unless otherwise indicated, an alkynyl group is unsubstituted.
The term “alkylene,” as used herein, refers to an alkyl group, as defined above, wherein one of the alkyl group's hydrogen atoms has been replaced with a bond. Non-limiting examples of alkylene groups include —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —CH(CH3)CH2CH2—, —CH(CH3)— and —CH2CH(CH3)CH2—. In one embodiment, an alkylene group has from 1 to about 6 carbon atoms. In another embodiment, an alkylene group is branched. In another embodiment, an alkylene group is linear. In one embodiment, an alkylene group is —CH2—. The term “C1-C6 alkylene” refers to an alkylene group having from 1 to 6 carbon atoms.
The term “aryl,” as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising from about 6 to about 14 carbon atoms. In one embodiment, an aryl group contains from about 6 to about 10 carbon atoms. An aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein below. In one embodiment, an aryl group can be optionally fused to a cycloalkyl or cycloalkanoyl group. Non-limiting examples of aryl groups include phenyl and naphthyl. In one embodiment, an aryl group is phenyl. Unless otherwise indicated, an aryl group is unsubstituted.
The term “arylene,” as used herein, refers to a bivalent group derived from an aryl group, as defined above, by removal of a hydrogen atom from a ring carbon of an aryl group. An arylene group can be derived from a monocyclic or multicyclic ring system comprising from about 6 to about 14 carbon atoms. In one embodiment, an arylene group contains from about 6 to about 10 carbon atoms. In another embodiment, an arylene group is a naphthylene group. In another embodiment, an arylene group is a phenylene group. An arylene group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein below. An arylene group is divalent and either available bond on an arylene group can connect to either group flanking the arylene group. For example, the group “A-arylene-B,” wherein the arylene group is:
is understood to represent both:
In one embodiment, an arylene group can be optionally fused to a cycloalkyl or cycloalkanoyl group. Non-limiting examples of arylene groups include phenylene and naphthalene. In one embodiment, an arylene group is unsubstituted. In another embodiment, an arylene group is:
Unless otherwise indicated, an arylene group is unsubstituted.
The term “cycloalkyl,” as used herein, refers to a non-aromatic mono- or multicyclic ring system comprising from about 3 to about 10 ring carbon atoms. In one embodiment, a cycloalkyl contains from about 5 to about 10 ring carbon atoms. In another embodiment, a cycloalkyl contains from about 3 to about 7 ring atoms. In another embodiment, a cycloalkyl contains from about 5 to about 6 ring atoms. The term “cycloalkyl” also encompasses a cycloalkyl group, as defined above, which is fused to an aryl (e.g., benzene) or heteroaryl ring. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Non-limiting examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl and adamantyl. A cycloalkyl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein below. In one embodiment, a cycloalkyl group is unsubstituted. The term “3 to 7-membered cycloalkyl” refers to a cycloalkyl group having from 3 to 7 ring carbon atoms. Unless otherwise indicated, a cycloalkyl group is unsubstituted. A ring carbon atom of a cycloalkyl group may be functionalized as a carbonyl group. An illustrative example of such a cycloalkyl group (also referred to herein as a “cycloalkanoyl” group) includes, but is not limited to, cyclobutanoyl:
The term “cycloalkenyl,” as used herein, refers to a non-aromatic mono- or multicyclic ring system comprising from about 4 to about 10 ring carbon atoms and containing at least one endocyclic double bond. In one embodiment, a cycloalkenyl contains from about 4 to about 7 ring carbon atoms. In another embodiment, a cycloalkenyl contains 5 or 6 ring atoms. Non-limiting examples of monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like. A cycloalkenyl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein below. A ring carbon atom of a cycloalkyl group may be functionalized as a carbonyl group. In one embodiment, a cycloalkenyl group is cyclopentenyl. In another embodiment, a cycloalkenyl group is cyclohexenyl. The term “4 to 7-membered cycloalkenyl” refers to a cycloalkenyl group having from 4 to 7 ring carbon atoms. Unless otherwise indicated, a cycloalkenyl group is unsubstituted.
The term “halo,” as used herein, means —F, —Cl, —Br or —I.
The term “haloalkyl,” as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a halogen. In one embodiment, a haloalkyl group has from 1 to 6 carbon atoms. In another embodiment, a haloalkyl group is substituted with from 1 to 3 F atoms. Non-limiting examples of haloalkyl groups include —CH2F, —CHF2, —CF3, —CH2Cl and —CCl3. The term “C1-C6 haloalkyl” refers to a haloalkyl group having from 1 to 6 carbon atoms.
The term “hydroxyalkyl,” as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an —OH group. In one embodiment, a hydroxyalkyl group has from 1 to 6 carbon atoms. Non-limiting examples of hydroxyalkyl groups include —CH2OH, —CH2CH2OH, —CH2CH2CH2OH and —CH2CH(OH)CH3. The term “C1-C6 hydroxyalkyl” refers to a hydroxyalkyl group having from 1 to 6 carbon atoms.
The term “heteroaryl,” as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms. In one embodiment, a heteroaryl group has 5 to 10 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heteroaryl group is bicyclic. A heteroaryl group can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein below. A heteroaryl group is joined via a ring carbon atom, and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. The term “heteroaryl” encompasses any fused polycyclic ring system in which at least one of the fused rings is aromatic. The term “heteroaryl” also encompasses a heteroaryl group, as defined above, which is fused to a benzene ring. Non-limiting examples of heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, benzimidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like, and all isomeric forms thereof. The term “heteroaryl” also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like. In one embodiment, a heteroaryl group is a 5-membered heteroaryl. In another embodiment, a heteroaryl group is a 6-membered heteroaryl. In another embodiment, a heteroaryl group comprises a 5- to 6-membered heteroaryl group fused to a benzene ring. Unless otherwise indicated, a heteroaryl group is unsubstituted.
The term “heteroarylene,” as used herein, refers to a bivalent group derived from an heteroaryl group, as defined above, by removal of a hydrogen atom from a ring carbon or ring heteroatom of a heteroaryl group. A heteroarylene group can be derived from a monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, wherein from 1 to 4 of the ring atoms are each independently O, N or S and the remaining ring atoms are carbon atoms. A heteroarylene group can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein below. A heteroarylene group is joined via a ring carbon atom or by a nitrogen atom with an open valence, and any nitrogen atom of a heteroarylene can be optionally oxidized to the corresponding N-oxide. The term “heteroarylene” also encompasses a heteroarylene group, as defined above, which is fused to a benzene ring. Non-limiting examples of heteroarylenes include pyridylene, pyrazinylene, furanylene, thienylene, pyrimidinylene, pyridonylene (including those derived from N-substituted pyridonyls), isoxazolylene, isothiazolylene, oxazolylene, oxadiazolylene, thiazolylene, pyrazolylene, thiophenylene, furazanylene, pyrrolylene, triazolylene, 1,2,4-thiadiazolylene, pyrazinylene, pyridazinylene, quinoxalinylene, phthalazinylene, oxindolylene, imidazo[1,2-a]pyridinylene, imidazo[2,1-b]thiazolylene, benzofurazanylene, indolylene, azaindolylene, benzimidazolylene, benzothienylene, quinolinylene, imidazolylene, benzimidazolylene, thienopyridylene, quinazolinylene, thienopyrimidylene, pyrrolopyridylene, imidazopyridylene, isoquinolinylene, benzoazaindolylene, 1,2,4-triazinylene, benzothiazolylene and the like, and all isomeric forms thereof. The term “heteroarylene” also refers to partially saturated heteroarylene moieties such as, for example, tetrahydroisoquinolylene, tetrahydroquinolylene, and the like. A heteroarylene group is divalent and either available bond on a heteroarylene ring can connect to either group flanking the heteroarylene group. For example, the group “A-heteroarylene-B,” wherein the heteroarylene group is:
is understood to represent both:
In one embodiment, a heteroarylene group is a monocyclic heteroarylene group or a bicyclic heteroarylene group. In another embodiment, a heteroarylene group is a monocyclic heteroarylene group. In another embodiment, a heteroarylene group is a bicyclic heteroarylene group. In still another embodiment, a heteroarylene group has from about 5 to about 10 ring atoms. In another embodiment, a heteroarylene group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heteroarylene group is bicyclic and has 9 or 10 ring atoms. In another embodiment, a heteroarylene group is a 5-membered monocyclic heteroarylene. In another embodiment, a heteroarylene group is a 6-membered monocyclic heteroarylene. In another embodiment, a bicyclic heteroarylene group comprises a 5 or 6-membered mono cyclic heteroarylene group fused to a benzene ring. Unless otherwise indicated, a heteroarylene group is unsubstituted.
The term “heterocycloalkyl,” as used herein, refers to a non-aromatic saturated monocyclic or multicyclic ring system comprising 3 to about 11 ring atoms, wherein from 1 to 4 of the ring atoms are independently O, S, N or Si, and the remainder of the ring atoms are carbon atoms. A heterocycloalkyl group can be joined via a ring carbon, ring silicon atom or ring nitrogen atom. In one embodiment, a heterocycloalkyl group is monocyclic and has from about 3 to about 7 ring atoms. In another embodiment, a heterocycloalkyl group is monocyclic has from about 4 to about 7 ring atoms. In another embodiment, a heterocycloalkyl group is bicyclic and has from about 7 to about 11 ring atoms. In still another embodiment, a heterocycloalkyl group is monocyclic and has 5 or 6 ring atoms. In one embodiment, a heterocycloalkyl group is monocyclic. In another embodiment, a heterocycloalkyl group is bicyclic. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Any —NH group in a heterocycloalkyl ring may exist protected such as, for example, as an —N(BOC), —N(Cbz), —N(Tos) group and the like; such protected heterocycloalkyl groups are considered part of this invention. The term “heterocycloalkyl” also encompasses a heterocycloalkyl group, as defined above, which is fused to an aryl (e.g., benzene) or heteroaryl ring. A heterocycloalkyl group can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein below. The nitrogen or sulfur atom of the heterocycloalkyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of monocyclic heterocycloalkyl rings include oxetanyl, piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, delta-lactam, delta-lactone, silacyclopentane, silapyrrolidine and the like, and all isomers thereof. Non-limiting illustrative examples of a silyl-containing heterocycloalkyl group include:
A ring carbon atom of a heterocycloalkyl group may be functionalized as a carbonyl group. An illustrative example of such a heterocycloalkyl group is:
In one embodiment, a heterocycloalkyl group is a 5-membered monocyclic heterocycloalkyl. In another embodiment, a heterocycloalkyl group is a 6-membered monocyclic heterocycloalkyl. The term “3 to 7-membered monocyclic cycloalkyl” refers to a monocyclic heterocycloalkyl group having from 3 to 7 ring atoms. The term “4 to 7-membered monocyclic cycloalkyl” refers to a monocyclic heterocycloalkyl group having from 4 to 7 ring atoms. The term “7 to 11-membered bicyclic heterocycloalkyl” refers to a bicyclic heterocycloalkyl group having from 7 to 11 ring atoms. Unless otherwise indicated, an heterocycloalkyl group is unsubstituted.
The term “heterocycloalkenyl,” as used herein, refers to a heterocycloalkyl group, as defined above, wherein the heterocycloalkyl group contains from 4 to 10 ring atoms, and at least one endocyclic carbon-carbon or carbon-nitrogen double bond. A heterocycloalkenyl group can be joined via a ring carbon or ring nitrogen atom. In one embodiment, a heterocycloalkenyl group has from 4 to 7 ring atoms. In another embodiment, a heterocycloalkenyl group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heterocycloalkenyl group is bicyclic. A heterocycloalkenyl group can optionally substituted by one or more ring system substituents, wherein “ring system substituent” is as defined above. The nitrogen or sulfur atom of the heterocycloalkenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of heterocycloalkenyl groups include 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluoro-substituted dihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like and the like. A ring carbon atom of a heterocycloalkenyl group may be functionalized as a carbonyl group. In one embodiment, a heterocycloalkenyl group is a 5-membered heterocycloalkenyl. In another embodiment, a heterocycloalkenyl group is a 6-membered heterocycloalkenyl. The term “4 to 7-membered heterocycloalkenyl” refers to a heterocycloalkenyl group having from 4 to 7 ring atoms. Unless otherwise indicated, a heterocycloalkenyl group is unsubstituted.
The term “ring system substituent,” as used herein, refers to a substituent group attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, -alkylene-aryl, -arylene-alkyl, -alkylene-heteroaryl, -alkenylene-heteroaryl, -alkynylene-heteroaryl, —OH, hydroxyalkyl, haloalkyl, —O-alkyl, —O-haloalkyl, -alkylene-O-alkyl, —O-aryl, —O-alkylene-aryl, acyl, —C(O)-aryl, halo, —NO2, —CN, —SF5, —C(O)OH, —C(O)O-alkyl, —C(O)O-aryl, —C(O)O-alkylene-aryl, —S(O)-alkyl, —S(O)2-alkyl, —S(O)-aryl, —S(O)2-aryl, —S(O)-heteroaryl, —S(O)2-heteroaryl, —S-alkyl, —S-aryl, —S-heteroaryl, —S-alkylene-aryl, —S-alkylene-heteroaryl, —S(O)2-alkylene-aryl, —S(O)2-alkylene-heteroaryl, —Si(alkyl)2, —Si(aryl)2, —Si(heteroaryl)2, —Si(alkyl)(aryl), —Si(alkyl)(cycloalkyl), —Si(alkyl)(heteroaryl), cycloalkyl, heterocycloalkyl, —O—C(O)-alkyl, —O—C(O)-aryl, —O—C(O)-cycloalkyl, —C(═N—CN)—NH2, —C(═NH)—NH2, —C(═NH)—NH(alkyl), —N(Y1)(Y2), -alkylene-N(Y1)(Y2), —C(O)N(Y1)(Y2) and —S(O)2N(Y1)(Y2), wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and -alkylene-aryl. “Ring system substituent” may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylenedioxy, ethylenedioxy, —C(CH3)2— and the like which form moieties such as, for example:
The term “silylalkyl,” as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a —Si(Rx)3 group, wherein each occurrence of Rx is independently C1-C6 alkyl, phenyl or a 3- to 6-membered cycloalkyl group. In one embodiment, a silylalkyl group has from 1 to 6 carbon atoms. In another embodiment, a silyl alkyl group contains a —Si(CH3)3 moiety. Non-limiting examples of silylalkyl groups include —CH2—Si(CH3)3 and —CH2CH2—Si(CH3)3.
The term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound’ or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term “in substantially purified form,” as used herein, refers to the physical state of a compound after the compound is isolated from a synthetic process (e.g., from a reaction mixture), a natural source, or a combination thereof. The term “in substantially purified form,” also refers to the physical state of a compound after the compound is obtained from a purification process or processes described herein or well-known to the skilled artisan (e.g., chromatography, recrystallization and the like), in sufficient purity to be characterizable by standard analytical techniques described herein or well-known to the skilled artisan.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
When a functional group in a compound is termed “protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991), Wiley, New York.
When any substituent or variable (e.g., alkyl, R6, Ra, etc.) occurs more than one time in any constituent or in Formula (I), its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term “prodrug” means a compound (e.g., a drug precursor) that is transformed in vivo to provide a Silyl-Containing Heterocyclic Compound or a pharmaceutically acceptable salt or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
For example, if a Silyl-Containing Heterocyclic Compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C1-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, and the like.
Similarly, if a Silyl-Containing Heterocyclic Compound contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N—(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkyl, α-amino(C1-C4)alkylene-aryl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, —P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
If a Silyl-Containing Heterocyclic Compound incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl-, RO-carbonyl-, NRR′-carbonyl- wherein R and R′ are each independently (C1-C10)alkyl, (C3-C7)cycloalkyl, benzyl, a natural α-aminoacyl, —C(OH)C(O)OY1 wherein Y1 is H, (C1-C6)alkyl or benzyl, —C(OY2)Y3 wherein Y2 is (C1-C4)alkyl and Y3 is (C1-C6)alkyl; carboxy(C1-C6)alkyl; amino(C1-C4)alkyl or mono-N— or di-N,N—(C1-C6)alkylaminoalkyl; —C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N— or di-N,N—(C1-C6)alkylamino morpholino; piperidin-1-yl or pyrrolidin-1-yl, and the like.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy group of a hydroxyl compound, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, t-butyl, sec-butyl or n-butyl), alkoxyalkyl (e.g., methoxymethyl), aralkyl (e.g., benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (e.g., phenyl optionally substituted with, for example, halogen, C1-4 alkyl, —O—(C1-4 alkyl) or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (e.g., L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1-20 alcohol or reactive derivative thereof, or by a 2,3-di(C6-24)acyl glycerol.
One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of solvates include ethanolates, methanolates, and the like. A “hydrate” is a solvate wherein the solvent molecule is water.
One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTechours., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than room temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example IR spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
The Silyl-Containing Heterocyclic Compounds can form salts which are also within the scope of this invention. Reference to a Silyl-Containing Heterocyclic Compound herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a Silyl-Containing Heterocyclic Compound contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. In one embodiment, the salt is a pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salt. In another embodiment, the salt is other than a pharmaceutically acceptable salt. Salts of the Compounds of Formula (I) may be formed, for example, by reacting a Silyl-Containing Heterocyclic Compound with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. In one embodiment, a compound of formula (I) is present as its dihydrochloride salt. In another embodiment, a compound of formula (I) is present as its dimesylate salt. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, t-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well-known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Sterochemically pure compounds may also be prepared by using chiral starting materials or by employing salt resolution techniques. Also, some of the Silyl-Containing Heterocyclic Compounds may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be directly separated using chiral chromatographic techniques.
It is also possible that the Silyl-Containing Heterocyclic Compounds may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. For example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, hydrates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. If a Silyl-Containing Heterocyclic Compound incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to apply equally to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
In the Compounds of Formula (I), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched Compounds of Formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates. In one embodiment, a Compound of Formula (I) has one or more of its hydrogen atoms replaced with deuterium.
Polymorphic forms of the Silyl-Containing Heterocyclic Compounds, and of the salts, solvates, hydrates, esters and prodrugs of the Silyl-Containing Heterocyclic Compounds, are intended to be included in the present invention.
The following abbreviations are used below and have the following meanings: Ac is acyl; AcOH is acetic acid; BF3.OEt2 is boron trifluoride etherate; BOC or Boc is tert-butyloxycarbonyl; Boc2O is Boc anhydride; Boc-Pro-OH is Boc protected proline; L-Boc-Val-OH is Boc protected L-valine; n-BuLi is n-butyllithium; dba is dibenzylideneacetone; DCM is dichloromethane; DIPEA is diisopropylethylamine; DME is dimethoxyethane; DMF is N,N-dimethylformamide; dppf is diphenylphosphinoferrocene; DMSO is dimethylsulfoxide; EtOAc is ethyl acetate; Et2O is diethyl ether; Et3N is triethylamine; HATU is O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; Hg(OAc)2 is mercuric acetate; HPLC is high performance liquid chromatography; HRMS is high resolution mass spectrometry; KOAc is potassium acetate; Lawesson's Reagent is 2,4-Bis(4-methoxyphenyl)-1,3-dithiadiphosphetane-2,4-disulfide;
The present invention provides Silyl-Containing Heterocyclic Compounds of Formula (I):
and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are defined above for the Compounds of Formula (I).
In one embodiment, for the Compounds of Formula (I), A and D are each independently selected from:
In another embodiment, for the Compounds of Formula (I), A and D are each independently selected from:
In one embodiment, for the Compounds of Formula (I), B is:
In one embodiment, for the Compounds of Formula (I), C is a bond.
In another embodiment, for the Compounds of Formula (I), C is a 5 or 6-membered monocyclic heteroarylene.
In another embodiment, for the Compounds of Formula (I), C is a 9 or 10-membered bicyclic heteroarylene.
In still another embodiment, for the Compounds of Formula (I), C is phenylene.
In another embodiment, for the Compounds of Formula (I), C is naphthylene.
In another embodiment, for the Compounds of Formula (I), C is
wherein R12 is an optional ring substituent selected from F, —OCH3, pyridyl, —OCH2CH2OH, —OCH2CH2OC(O)CH3, cyclopropyl and thiophenyl
In yet another embodiment, for the Compounds of Formula (I), C is:
In one embodiment, for the Compounds of Formula (I), each occurrence of each occurrence of R4 is independently:
wherein Ra is selected from C1-C6 alkyl, C1-C6 haloalkyl, silylalkyl, benzyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl or heteroaryl; Rb is selected from H, C1-C6 alkyl, C1-C6 haloalkyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl and heteroaryl; and each occurrence of R1 is independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl, 3- to 7-membered cycloalkyl, 4- to 7-membered heterocycloalkyl, aryl and heteroaryl, wherein two R1 groups on the same nitrogen atom, together with the nitrogen atom to which they are attached, can optionally join to form a 5 or 6-membered heterocycloalkyl ring.
In another embodiment, for the Compounds of Formula (I), each occurrence of R4 is independently:
wherein Ra is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, tetrahydropyranyl, benzyl and phenyl and R1 is selected from methyl, ethyl and isopropyl.
In another embodiment, for the Compounds of Formula (I), each occurrence of R4 is independently:
wherein each occurrence R1 is methyl or ethyl.
In still another embodiment, for the Compounds of Formula (I), each occurrence of R4 is independently selected from:
In another embodiment, for the Compounds of Formula (I), each occurrence of R4 is:
In one embodiment, for the Compounds of Formula (I), A and D are each independently selected from:
and each occurrence of R4 is independently selected from:
In one embodiment, for the Compounds of Formula (I), A and D are each independently selected from:
and each occurrence of R4 is:
In one embodiment, for the Compounds of Formula (I), A and D are each independently selected from:
B is a 5-membered monocyclic heteroarylene;
C is:
wherein R12 is an optional ring substituent selected from F, —OCH3, pyridyl, —OCH2CH2OH, —OCH2CH2OC(O)CH3, cyclopropyl and thiophenyl; and
each occurrence of R4 is independently selected from:
In one embodiment, the Compounds of Formula (I) have the formula (Ia):
and pharmaceutically acceptable salts thereof,
wherein:
C is phenylene or naphthylene, wherein said phenylene group and said naphthylene group can be optionally and independently substituted with up to two groups, which can be the same or different, and are selected from halo, 3- to 7-membered cycloalkyl, 5- or 6-membered heteroaryl, —O—(C1-C6 alkyl), —O—(C1-C6 hydroxyalkyl), or —O—(C1-C6 alkylene)-OC(O)—(C1-C6 alkyl);
each occurrence of Z is independently —Si(Rx)2—, —C(Ry)2— or such that at least one occurrence of Z is —Si(Rx)2—;
each occurrence of Rx is independently C1-C6 alkyl or two Rx groups that are attached to the same Si atom, combine to form a —(CH2)4— or —(CH2)5— group; and
each occurrence of Ry is independently H or F, or two Ry groups on the same ring carbon atom, together with the carbon atom to which they are attached, can join to form a spirocyclic 3 to 7-membered cycloalkyl group;
Rz is H, or when Z is —C(Ry)2—, Rz and one Ry group, together with the ring carbon atoms to which they are attached, can optionally combine to form a 3 to 7-membered cycloalkyl group;
each occurrence of R1 is independently C1-C6 alkyl;
each occurrence of R4 is independently —C(O)CH(R7a)NHC(O)OR1 or —C(O)—CH(R7b)—N(R1)2;
each occurrence of R7a is independently C1-C6 alkyl, aryl, benzyl, 3- to 7-membered cycloalkyl or 4 to 7-membered heterocycloalkyl;
each occurrence of R7b is aryl; and
R12 is H, F or Cl.
In one embodiment, for the Compounds of Formula (Ia), one occurrence of Z is —Si(CH3)2—.
In another embodiment, for the Compounds of Formula (Ia), one occurrence of Z is CH2, —CH(F) or —CF2—.
In another embodiment, for the Compounds of Formula (Ia), one occurrence of Z is —Si(CH3)2— and the other occurrence of Z is CH2, —CH(F) or —CF2—.
In one embodiment, for the Compounds of Formula (Ia), C is phenylene or naphthylene, each of which can be optionally substituted with F, —O—(C1-C6 alkyl), —OCH2CH2OC(O)CH3, cyclopropyl or thiophenyl.
In another embodiment, for the Compounds of Formula (Ia), C is:
In one embodiment, for the Compounds of Formula (Ia), each occurrence of R4 is independently selected from:
In one embodiment, the Compounds of Formula (I) have the formula (Ib):
each occurrence of R1 is independently C1-C6 alkyl;
each occurrence of R4 is independently —C(O)CH(R7)C(O)OR1 or —C(O)CH(R7)N(R1)2;
each occurrence of R7 is independently phenyl or 4 to 7-membered heterocycloalkyl;
each occurrence of R12a is H or halo; and
each occurrence of R12 is H, or both R12 groups, together with the carbon atoms to which they are attached, join to form a 3 to 7-membered cycloalkyl group.
In one embodiment, for the compounds of formula (Ib), each occurrence of R12 is H.
In one embodiment, for the compounds of formula (Ib), R12a is H.
In another embodiment, for the compounds of formula (Ib), R12a is Cl.
In one embodiment, for the compounds of formula (Ib), both R12 groups, together with the carbon atoms to which they are attached, join to form a 3 to 7-membered cycloalkyl group.
In another embodiment, for the compounds of formula (Ib), both R12 groups, together with the carbon atoms to which they are attached, join to form a cyclopropyl group.
In one embodiment, for the compounds of formula (Ib), each occurrence of R4 is —C(O)CH(R7)C(O)OR1.
In one embodiment, for the compounds of formula (Ib), each occurrence of R4 is —C(O)CH(R7)N(R1)2.
In one embodiment, for the compounds of formula (Ib), each occurrence of R4 is:
In one embodiment, for the compounds of formula (Ib), each occurrence of R4 is:
In one embodiment, variables A, B, C, D, M1 and R2 in the Compounds of Formula (I) are selected independently from each other.
In another embodiment, a Compound of Formula (I) is in substantially purified form.
Other embodiments of the present invention include the following:
The present invention also includes a compound of the present invention for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inhibiting HCV replication or (b) treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection. In these uses, the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators.
Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(k) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt or hydrate as appropriate.
It is further to be understood that the embodiments of compositions and methods provided as (a) through (k) above are understood to include all embodiments of the compounds, including such embodiments as result from combinations of embodiments.
Non-limiting examples of the Compounds of Formula (I) include compounds 1-118, as set forth in the Examples below, and pharmaceutically acceptable salts thereof.
The Compounds of Formula (I) may be prepared from known or readily prepared starting materials, following methods known to one skilled in the art of organic synthesis. Methods useful for making the Compounds of Formula (I) are set forth in the Examples below and generalized in Schemes 1-8 below. Alternative synthetic pathways and analogous structures will be apparent to those skilled in the art of organic synthesis. All stereoisomers and tautomeric forms of the compounds are contemplated.
Some commercially available starting materials and intermediates used for the synthesis of the Compounds of Formula (I) are available which contain intact fused tricyclic tricyclic ring systems. These starting materials and intermediates are available from commercial suppliers such as Sigma-Aldrich (St. Louis, Mo.) and Acros Organics Co. (Fair Lawn, N.J.). Such starting materials and intermediates compounds are used as received. When such fused tricyclic moieties are not commercially available, they can be prepared using methods well-known to those skilled in the art of organic synthesis. Such synthetic methods include, but are not limited to, those described in Kricka et al., J. Chem. Soc. Perkin Trans 1, 859-863 (1973); Kricka et al., Chem. Rew., 74, 101-123, (1974); Kurfuerst et al., Coll. Czech. Chem. Comm., 54, 1705-1715, (1989); Saroja et al., J. Org. Chem. 69, 987-990, (2004); Fanta et al., Synth. 9-21, (1974), U.S. Patent Publication No. US2005038037; and International Publication No. WO2004039859.
Scheme 1 shows a method useful for making the naphthyl imidazole compounds of formula A7 and A8, which are useful intermediates for making the Compounds of Formula (I).
Nitration of bromonaphthyl acetamide A1 provides nitro analog A2 (J. Am. Chem. Soc, 73:4297 (1997)). The removal of acetyl group under acidic conditions followed by reduction of the nitro group should afford diaminonaphthalene A4. Coupling of the aniline to a cyclic or acyclic N-protected α-amino acid A5 gives an amide of formula A6, which upon heating in acetic acid will cyclize to provide tricyclic bormonaphthylimidazole A7. The bromide could be converted to a boronate A8 with a palladium catalyst.
Scheme 2 shows a method useful for making the quinolineimidazole compounds of formula B6, which are useful intermediates for making the Compounds of Formula (I).
Commercially available aminonitroquinoline B1 can be reduced to diaminoquinoline B2, which is then coupled to a cyclic or acyclic N-protected α-amino acid A5 to providean amide B3. It can then be cyclized to quinolineimidazole B4 under acidic conditions. N-oxide B5 can then be obtained with m-chloroperbenzoic acid. Upon treatment with phosphorous oxychloride, B5 should give the desired chloroquinoline B6, which can used in Suzuki coupling reactions.
Scheme 3 shows a method useful for making the boronic acid compounds of formula C4, which are useful intermediates for making the Compounds of Formula (I), where in “C” is a monocyclic 5 to 6-membered heteroaryl (examples: thiophene or pyridine).
The Suzuki coupling partner C3 or C4 can be prepared from commercially available heteroaryl bromoacetyl compound of formula C1 (Scheme 3). When treated with an N-protected amino acid (PG-AA-OH) in the presence of an amine base, e.g., DIPEA, a ketoester C2 is formed. If heated together with ammonium acetate, the ketoester is converted to the desired imidazole derivative C3. The bromide can then be converted to a boronate C4 with a palladium catalyzed reaction.
Scheme 4 shows methods useful for making the compounds of formula C1 and C3, which are useful intermediates for making the Compounds of Formula (I), wherein variable C is other than a bond and B is an imidazole ring.
When heteroaryl bromoacetyl C1 is not commercially available, it can be prepared by performing Friedel-Crafts acylation on a heteroaryl bromide of formula D1 using well-known methods, (e.g., those described in Kricka et al., J. Chem. Soc. Perkin Trans 1, 859-863 (1973), and Kricka et al., Chem. Rew., 74, 101-123, (1974)) to provide the acylated products of formula D2. A compound of formula D2 can then be brominated using bromine, for example, to provide the compounds of formula C1.
On the other hand, bromo-iodo substituted heteroaromatic rings D3 can undergo a Stille coupling with (α-ethoxyvinyl) tributylstannane in the presence of a palladium catalyst using the methods including, but not limited to those described in Choshi et al., J. Org. Chem., 62:2535-2543 (1997), and Scott et al., J. Am. Chem. Soc., 106:4630 (1984)), to provide the ethyl-vinyl ether intermediate D4. Treating D4 with N-bromosuccimide gives the desired bromoacetyl intermediate Cl, which can then be elaborated to advanced intermediates C3 or C4 for Suzuki coupling.
Alternatively, a heteroaromatic dibromide of formula D5 can be lithiated using n-butyl lithium and then quenched with N-Boc-glycine Weinreb amide to provide a Boc-protected β-keto amino compound of formula D6. Removal of the Boc group using TFA, for example, provides an amine compound of formula D7, which can then be coupled with an N-protected amino acid using typical amide bond forming reagents such as HATU to provide a ketoamide compound of formula D8. Upon heated in the presence of ammonium acetate, compound D8 can be cyclized to the imidazole analog of formula C3.
Scheme 5 shows a method useful for making the boronic acid compounds of formula E4, which are useful intermediates for making the Compounds of Formula (I).
A heteroaromatic diamine E1 could be converted to a bicyclic imidazole E3 using the two step coupling-cyclization procedure described, for example, in Scheme 3. The corresponding boronate E4 can then easily be obtained from bromide E3 via well-known chemistry. Both E3 and E4 can be used as intermediate coupling partners in a Suzuki coupling process to provide the Compound of Formula (I).
Scheme 6 shows methods useful for making the Compounds of Formula (I) via a Suzuki Coupling process.
A Suzuki coupling between protected imidazole boronate C4 (or boronic acid, not shown) and the fused bi-aryl tricyclic bromide A6 using, for example, the methods described in Angew Chem. Int. Ed. Engl., 40, 4544 (2001) provide the compounds of formula G1. Compounds of formula G1 can then be used to provide compounds of formula G2 by removal of the nitrogen protecting groups of G1. An appropriate cap of group R can be added to the deprotected amino groups of G2 using reactions including, but not limited to acylation (with an acyl chloride or amino acid coupling reagent such as HATU or HOBt/EDCI), sulfonylation (with a sulfonyl chloride) or alkylation (with alkyl halide or reductive amination) to provide the desired Compounds of Formula (I).
Scheme 7 shows alternative methods useful for making the Compounds of Formula (I) via a Suzuki Coupling process.
Similarly, a bicyclic bromide of formula E3 and fused tricyclic boronate of formula A7 can be joined using the methods described in Scheme 6 above, to provide coupled intermediates of formula H1. The compounds of formula H1 can then be further elaborated using, for example, the methods described in Scheme 6 above, to provide the Compounds of Formula (I), wherein C is a bond and B is a bicyclic heteroarylene group.
A boronate of formula C4 and chloroquinolineimidazole of formula B6 can be coupled under Suzuki coupling conditions similar to the methods described above to provide products of formula I1, which can be transformed to the final targets of formula I3, using methods well-known to those skilled in the art of organic synthesis, including those described in Scheme 6 above.
In some of the Silyl-Containing Heterocyclic Compounds contemplated in Schemes 1-8, the amino acids (such as, but not limited to proline, 4,4-difluoroproline, (S)-2-piperidine carboxylic acid, valine, alanine, norvaline, etc.) are incorporated as part of structures. Methods have been described in the general literature as well as in Banchard US 2009/0068140 for the preparation of such amino acid-derived intermediates.
One skilled in the art of organic synthesis will recognize that the synthesis of the Compounds of Formula (I) may require protection of certain functional groups (i.e., derivatization for the purpose of chemical compatibility with a particular reaction condition). Suitable protecting groups for the various functional groups of these compounds and methods for their installation and removal can be found in Greene et al., Protective Groups in Organic Synthesis, Wiley-Interscience, New York, (1999).
One skilled in the art of organic synthesis will also recognize that one route for the synthesis of the Compounds of Formula (I) may be more desirable depending on the choice of appendage substituents. Additionally, one skilled in the art will recognize that in some cases the order of reactions may differ from that presented herein to avoid functional group incompatibilities and can amend the synthetic route accordingly.
One skilled in the art of organic synthesis will recognize that the synthesis of the Compounds of Formula (I) may require the construction of an amide bond. Methods useful for making such amide bonds, include but are not limited to, the use of a reactive carboxy derivative (e.g., an acid halide, or ester at elevated temperatures) or the use of an acid with a coupling reagent (e.g., HOBt, EDCI, DCC, HATU, PyBrop) with an amine.
The preparation of various monocyclic and polycyclic heterocyclic ring systems contemplated in this invention have been described in the literature and in compendia such as “Comprehensive Heterocyclic Chemistry” editions I, II and III, published by Elsevier and edited by A. R. Katritzky & R J K Taylor. Manipulation of the required substitution patterns have also been described in the available chemical literature as summarized in compendia such as “Comprehensive Organic Chemistry” published by Elsevier and edited by D H R. Barton and W. D. Ollis; “Comprehensive Organic Functional Group Transformations” edited by edited by A. R. Katritzky & R J K Taylor and “Comprehensive Organic Transformation” published by Wily-CVH and edited by R. C. Larock.
The starting materials used and the intermediates prepared using the methods set forth in the Schemes above may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and alike. Such materials can be characterized using conventional means, including physical constants and spectral data.
The Silyl-Containing Heterocyclic Compounds are useful in human and veterinary medicine for treating or preventing a viral infection in a patient. In one embodiment, the Silyl-Containing Heterocyclic Compounds can be inhibitors of viral replication. In another embodiment, the Silyl-Containing Heterocyclic Compounds can be inhibitors of HCV replication. Accordingly, the Silyl-Containing Heterocyclic Compounds are useful for treating viral infections, such as HCV. In accordance with the invention, the Silyl-Containing Heterocyclic Compounds can be administered to a patient in need of treatment or prevention of a viral infection.
Accordingly, in one embodiment, the invention provides methods for treating a viral infection in a patient comprising administering to the patient an effective amount of at least one Silyl-Containing Heterocyclic Compound or a pharmaceutically acceptable salt thereof.
The Silyl-Containing Heterocyclic Compounds can be useful for treating or preventing a viral infection caused by the Flaviviridae family of viruses.
Examples of Flaviviridae infections that can be treated or prevented using the present methods include but are not limited to, dengue fever, Japanese encephalitis, Kyasanur Forest disease, Murray Valley encephalitis, St. Louis encephalitis, Tick-borne encephalitis, West Nile encephalitis, yellow fever and Hepatitis C Virus (HCV) infection.
In one embodiment, the Flaviviridae infection being treated is hepatitis C virus infection.
The Silyl-Containing Heterocyclic Compounds are useful in the inhibition of HCV (e.g., HCV NS5A), the treatment of HCV infection and/or reduction of the likelihood or severity of symptoms of HCV infection and the inhibition of HCV viral replication and/or HCV viral production in a cell-based system. For example, the Silyl-Containing Heterocyclic Compounds are useful in treating infection by HCV after suspected past exposure to HCV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery or other medical procedures.
In one embodiment, the hepatitis C infection is acute hepatitis C. In another embodiment, the hepatitis C infection is chronic hepatitis C.
Accordingly, in one embodiment, the invention provides methods for treating HCV infection in a patient, the methods comprising administering to the patient an effective amount of at least one Silyl-Containing Heterocyclic Compound or a pharmaceutically acceptable salt thereof. In a specific embodiment, the amount administered is effective to treat or prevent infection by HCV in the patient. In another specific embodiment, the amount administered is effective to inhibit HCV viral replication and/or viral production in the patient.
The Silyl-Containing Heterocyclic Compounds are also useful in the preparation and execution of screening assays for antiviral compounds. For example the Silyl-Containing Heterocyclic Compounds are useful for identifying resistant HCV replicon cell lines harboring mutations within NS5A, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the Silyl-Containing Heterocyclic Compounds are useful in establishing or determining the binding site of other antivirals to the HCV replicase.
The compositions and combinations of the present invention can be useful for treating a patient suffering from infection related to any HCV genotype. HCV types and subtypes may differ in their antigenicity, level of viremia, severity of disease produced, and response to interferon therapy as described in Holland et al., Pathology, 30(2):192-195 (1998). The nomenclature set forth in Simmonds et al., J Gen Virol, 74(Pt11):2391-2399 (1993) is widely used and classifies isolates into six major genotypes, 1 through 6, with two or more related subtypes, e.g., 1a and 1b. Additional genotypes 7-10 and 11 have been proposed, however the phylogenetic basis on which this classification is based has been questioned, and thus types 7, 8, 9 and 11 isolates have been reassigned as type 6, and type 10 isolates as type 3 (see Lamballerie et al., J Gen Virol, 78(Pt1):45-51 (1997)). The major genotypes have been defined as having sequence similarities of between 55 and 72% (mean 64.5%), and subtypes within types as having 75%-86% similarity (mean 80%) when sequenced in the NS-5 region (see Simmonds et al., J Gen Virol, 75(Pt 5):1053-1061 (1994)).
In another embodiment, the present methods for treating or preventing HCV infection can further comprise the administration of one or more additional therapeutic agents which are not Silyl-Containing Heterocyclic Compounds.
In one embodiment, the additional therapeutic agent is an antiviral agent.
In another embodiment, the additional therapeutic agent is an immunomodulatory agent, such as an immunosuppressive agent.
Accordingly, in one embodiment, the present invention provides methods for treating a viral infection in a patient, the method comprising administering to the patient: (i) at least one Silyl-Containing Heterocyclic Compound, or a pharmaceutically acceptable salt thereof, and (ii) at least one additional therapeutic agent that is other than a Silyl-Containing Heterocyclic Compound, wherein the amounts administered are together effective to treat or prevent a viral infection.
When administering a combination therapy of the invention to a patient, therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like. The amounts of the various actives in such combination therapy may be different amounts (different dosage amounts) or same amounts (same dosage amounts). Thus, for non-limiting illustration purposes, a Silyl-Containing Heterocyclic Compound and an additional therapeutic agent may be present in fixed amounts (dosage amounts) in a single dosage unit (e.g., a capsule, a tablet and the like).
In one embodiment, the at least one Silyl-Containing Heterocyclic Compound is administered during a time when the additional therapeutic agent(s) exert their prophylactic or therapeutic effect, or vice versa.
In another embodiment, the at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating a viral infection.
In another embodiment, the at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating a viral infection.
In still another embodiment, the at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) act synergistically and are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating a viral infection.
In one embodiment, the at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) are present in the same composition. In one embodiment, this composition is suitable for oral administration. In another embodiment, this composition is suitable for intravenous administration. In another embodiment, this composition is suitable for subcutaneous administration. In still another embodiment, this composition is suitable for parenteral administration.
Viral infections and virus-related disorders that can be treated or prevented using the combination therapy methods of the present invention include, but are not limited to, those listed above.
In one embodiment, the viral infection is HCV infection.
The at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) can act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of therapy without reducing the efficacy of therapy.
In one embodiment, the administration of at least one Silyl-Containing Heterocyclic Compound and the additional therapeutic agent(s) may inhibit the resistance of a viral infection to these agents.
Non-limiting examples of additional therapeutic agents that may be useful in the present compositions and methods include an interferon, an immunomodulator, a viral replication inhibitor, an antisense agent, a therapeutic vaccine, a viral polymerase inhibitor, a nucleoside inhibitor, a viral protease inhibitor, a viral helicase inhibitor, a virion production inhibitor, a viral entry inhibitor, a viral assembly inhibitor, an antibody therapy (monoclonal or polyclonal), and any agent useful for treating an RNA-dependent polymerase-related disorder.
In one embodiment, the additional therapeutic agent is a viral protease inhibitor.
In another embodiment, the additional therapeutic agent is a viral replication inhibitor.
In another embodiment, the additional therapeutic agent is an HCV NS3 protease inhibitor.
In still another embodiment, the additional therapeutic agent is an HCV NS5B polymerase inhibitor.
In another embodiment, the additional therapeutic agent is a nucleoside inhibitor.
In another embodiment, the additional therapeutic agent is an interferon.
In yet another embodiment, the additional therapeutic agent is an HCV replicase inhibitor.
In another embodiment, the additional therapeutic agent is an antisense agent.
In another embodiment, the additional therapeutic agent is a therapeutic vaccine.
In a further embodiment, the additional therapeutic agent is a virion production inhibitor.
In another embodiment, the additional therapeutic agent is an antibody therapy.
In another embodiment, the additional therapeutic agent is an HCV NS2 inhibitor.
In still another embodiment, the additional therapeutic agent is an HCV NS4A inhibitor.
In another embodiment, the additional therapeutic agent is an HCV NS4B inhibitor.
In another embodiment, the additional therapeutic agent is an HCV NS5A inhibitor
In yet another embodiment, the additional therapeutic agent is an HCV NS3 helicase inhibitor.
In another embodiment, the additional therapeutic agent is an HCV IRES inhibitor.
In another embodiment, the additional therapeutic agent is an HCV p7 inhibitor.
In a further embodiment, the additional therapeutic agent is an HCV entry inhibitor.
In another embodiment, the additional therapeutic agent is an HCV assembly inhibitor.
In one embodiment, the additional therapeutic agents comprise a viral protease inhibitor and a viral polymerase inhibitor.
In still another embodiment, the additional therapeutic agents comprise a viral protease inhibitor and an immunomodulatory agent.
In yet another embodiment, the additional therapeutic agents comprise a polymerase inhibitor and an immunomodulatory agent.
In another embodiment, the additional therapeutic agents comprise a viral protease inhibitor and a nucleoside.
In another embodiment, the additional therapeutic agents comprise an immunomodulatory agent and a nucleoside.
In one embodiment, the additional therapeutic agents comprise an HCV protease inhibitor and an HCV polymerase inhibitor.
In another embodiment, the additional therapeutic agents comprise a nucleoside and an HCV NS5A inhibitor.
In another embodiment, the additional therapeutic agents comprise a viral protease inhibitor, an immunomodulatory agent and a nucleoside.
In a further embodiment, the additional therapeutic agents comprise a viral protease inhibitor, a viral polymerase inhibitor and an immunomodulatory agent.
In another embodiment, the additional therapeutic agent is ribavirin.
HCV polymerase inhibitors useful in the present compositions and methods include, but are not limited to, VP-19744 (Wyeth/ViroPharma), PSI-7851 (Pharmasset), RG7128 (Roche/Pharmasset), PSI-7977 (Pharmasset), PSI-938 (Pharmasset), PSI-879 (Pharmasset), PSI-661 (Pharmasset), PF-868554/filibuvir (Pfizer), VCH-759/VX-759 (ViroChem Pharma/Vertex), HCV-371 (Wyeth/VirroPharma), HCV-796 (Wyeth/ViroPharma), IDX-184 (Idenix), IDX-375 (Idenix), NM-283 (Idenix/Novartis), GL-60667 (Genelabs), JTK-109 (Japan Tobacco), PSI-6130 (Pharmasset), R1479 (Roche), R-1626 (Roche), R-7128 (Roche), MK-0608 (Isis/Merck), INX-8014 (Inhibitex), INX-8018 (Inhibitex), INX-189 (Inhibitex), GS 9190 (Gilead), A-848837 (Abbott), ABT-333 (Abbott), ABT-072 (Abbott), A-837093 (Abbott), BI-207127 (Boehringer-Ingelheim), BILB-1941 (Boehringer-Ingelheim), MK-3281 (Merck), VCH-222NX-222 (ViroChem/Vertex), VCH-916 (ViroChem), VCH-716(ViroChem), GSK-71185 (Glaxo SmithKline), ANA598 (Anadys), GSK-625433 (Glaxo SmithKline), XTL-2125 (XTL Biopharmaceuticals), and those disclosed in Ni et al., Current Opinion in Drug Discovery and Development, 7(4):446 (2004); Tan et al., Nature Reviews, 1:867 (2002); and Beaulieu et al., Current Opinion in Investigational Drugs, 5:838 (2004).
Other HCV polymerase inhibitors useful in the present compositions and methods include, but are not limited to, those disclosed in International Publication Nos. WO 08/082,484, WO 08/082,488, WO 08/083,351, WO 08/136,815, WO 09/032,116, WO 09/032,123, WO 09/032,124 and WO 09/032,125.
Interferons useful in the present compositions and methods include, but are not limited to, interferon alfa-2a, interferon alfa-2b, interferon alfacon-1 and PEG-interferon alpha conjugates. “PEG-interferon alpha conjugates” are interferon alpha molecules covalently attached to a PEG molecule. Illustrative PEG-interferon alpha conjugates include interferon alpha-2a (Roferon™, Hoffman La-Roche, Nutley, N.J.) in the form of pegylated interferon alpha-2a (e.g., as sold under the trade name Pegasys™), interferon alpha-2b (Intron™, from Schering-Plough Corporation) in the form of pegylated interferon alpha-2b (e.g., as sold under the trade name PEG-Intron™ from Schering-Plough Corporation), interferon alpha-2b-XL (e.g., as sold under the trade name PEG-Intron™), interferon alpha-2c (Berofor Alpha™, Boehringer Ingelheim, Ingelheim, Germany), PEG-interferon lambda (Bristol-Myers Squibb and ZymoGenetics), interferon alfa-2b alpha fusion polypeptides, interferon fused with the human blood protein albumin (Albuferon™, Human Genome Sciences), Omega Interferon (Intarcia), Locteron controlled release interferon (Biolex/OctoPlus), Biomed-510 (omega interferon), Peg-IL-29 (ZymoGenetics), Locteron CR (Octoplus), R-7025 (Roche), IFN-α-2b-XL (Flamel Technologies), belerofon (Nautilus) and consensus interferon as defined by determination of a consensus sequence of naturally occurring interferon alphas (Infergen™, Amgen, Thousand Oaks, Calif.).
Antibody therapy agents useful in the present compositions and methods include, but are not limited to, antibodies specific to IL-10 (such as those disclosed in US Patent Publication No. US2005/0101770, humanized 12G8, a humanized monoclonal antibody against human IL-10, plasmids containing the nucleic acids encoding the humanized 12G8 light and heavy chains were deposited with the American Type Culture Collection (ATCC) as deposit numbers PTA-5923 and PTA-5922, respectively), and the like).
Examples of viral protease inhibitors useful in the present compositions and methods include, but are not limited to, an HCV protease inhibitor.
HCV protease inhibitors useful in the present compositions and methods include, but are not limited to, those disclosed in U.S. Pat. Nos. 7,494,988, 7,485,625, 7,449,447, 7,442,695, 7,425,576, 7,342,041, 7,253,160, 7,244,721, 7,205,330, 7,192,957, 7,186,747, 7,173,057, 7,169,760, 7,012,066, 6,914,122, 6,911,428, 6,894,072, 6,846,802, 6,838,475, 6,800,434, 6,767,991, 5,017,380, 4,933,443, 4,812,561 and 4,634,697; U.S. Patent Publication Nos. US20020068702, US20020160962, US20050119168, US20050176648, US20050209164, US20050249702 and US20070042968; and International Publication Nos. WO 03/006490, WO 03/087092, WO 04/092161 and WO 08/124,148.
Additional HCV protease inhibitors useful in the present compositions and methods include, but are not limited to, VX-950 (Telaprevir, Vertex), VX-500 (Vertex), VX-813 (Vertex), VBY-376 (Virobay), BI-201335 (Boehringer Ingelheim), TMC-435 (Medivir/Tibotec), ABT-450 (Abbott/Enanta), TMC-435350 (Medivir), RG7227 (Danoprevir, InterMune/Roche), EA-058 (Abbott/Enanta), EA-063 (Abbott/Enanta), GS-9256 (Gilead), IDX-320 (Idenix), ACH-1625 (Achillion), ACH-2684 (Achillion), GS-9132 (Gilead/Achillion), ACH-1095 (Gilead/Achillon), IDX-136 (Idenix), IDX-316 (Idenix), ITMN-8356 (InterMune), ITMN-8347 (InterMune), ITMN-8096 (InterMune), ITMN-7587 (InterMune), BMS-650032 (Bristol-Myers Squibb), VX-985 (Vertex) and PHX1766 (Phenomix).
Further examples of HCV protease inhibitors useful in the present compositions and methods include, but are not limited to, those disclosed in Landro et al., Biochemistry, 36(30:9340-9348 (1997); Ingallinella et al., Biochemistry, 37(25):8906-8914 (1998); Llinàs-Brunet et al., Bioorg Med Chem Lett, 8(13):1713-1718 (1998); Martin et al., Biochemistry, 37(33):11459-11468 (1998); Dimasi et al., J Virol, 71(10):7461-7469 (1997); Martin et al., Protein Eng, 10(5):607-614 (1997); Elzouki et al., J Hepat, 27(1):42-48 (1997); Bio World Today, 9(217):4 (Nov. 10, 1998); U.S. Patent Publication Nos. US2005/0249702 and US 2007/0274951; and International Publication Nos. WO 98/14181, WO 98/17679, WO 98/17679, WO 98/22496 and WO 99/07734 and WO 05/087731.
Further examples of HCV protease inhibitors useful in the present compositions and methods include, but are not limited to, the following compounds:
and pharmaceutically acceptable salts thereof.
Viral replication inhibitors useful in the present compositions and methods include, but are not limited to, HCV replicase inhibitors, IRES inhibitors, NS4A inhibitors, NS3 helicase inhibitors, NS5A inhibitors, NS5B inhibitors, ribavirin, AZD-2836 (Astra Zeneca), viramidine, A-831 (Arrow Therapeutics), EDP-239 (Enanta), ACH-2928 (Achillion), GS-5885 (Gilead); an antisense agent or a therapeutic vaccine.
Viral entry inhibitors useful as second additional therapeutic agents in the present compositions and methods include, but are not limited to, PRO-206 (Progenies), REP-9C (REPICor), SP-30 (Samaritan Pharmaceuticals) and ITX-5061 (iTherx).
HCV NS4A inhibitors useful in the useful in the present compositions and methods include, but are not limited to, those disclosed in U.S. Pat. Nos. 7,476,686 and 7,273,885; U.S. Patent Publication No. US20090022688; and International Publication Nos. WO 2006/019831 and WO 2006/019832. Additional HCV NS4A inhibitors useful as second additional therapeutic agents in the present compositions and methods include, but are not limited to, AZD2836 (Astra Zeneca), ACH-1095 (Achillion) and ACH-806 (Achillion).
HCV NS5A inhibitors useful in the present compositions and methods include, but are not limited to, A-832 (Arrow Therpeutics), PPI-461 (Presidio), PPI-1301 (Presidio) and BMS-790052 (Bristol-Myers Squibb).
HCV replicase inhibitors useful in the present compositions and methods include, but are not limited to, those disclosed in U.S. Patent Publication No. US20090081636.
Therapeutic vaccines useful in the present compositions and methods include, but are not limited to, IC41 (Intercell Novartis), CSL123 (Chiron/CSL), GI 5005 (Globeimmune), TG-4040 (Transgene), GNI-103 (GENimmune), Hepavaxx C (ViRex Medical), ChronVac-C (Inovio/Tripep), PeviPROTM (Pevion Biotect), HCV/MF59 (Chiron/Novartis), MBL-HCV1 (MassBiologics), G1-5005 (GlobeImmune), CT-011 (CureTech/Teva) and Civacir (NABI).
Examples of further additional therapeutic agents that may be useful in the present compositions and methods include, but are not limited to, Ritonavir (Abbott), TT033 (Benitec/Tacere Bio/Pfizer), Sirna-034 (Sirna Therapeutics), GNI-104 (GENimmune), G1-5005 (GlobeImmune), IDX-102 (Idenix), Levovirin™ (ICN Pharmaceuticals, Costa Mesa, Calif.); Humax (Genmab), ITX-2155 (Ithrex/Novartis), PRO206 (Progenies), HepaCide-I (NanoVirocides), MX3235 (Migenix), SCY-635 (Scynexis); KPE02003002 (Kemin Pharma), Lenocta (VioQuest Pharmaceuticals), IET-Interferon Enhancing Therapy (Transition Therapeutics), Zadaxin (SciClone Pharma), VP 50406™ (Viropharma, Incorporated, Exton, Pa.); Taribavirin (Valeant Pharmaceuticals); Nitazoxanide (Romark); Debio 025 (Debiopharm); GS-9450 (Gilead); PF-4878691 (Pfizer); ANA773 (Anadys); SCV-07 (SciClone Pharmaceuticals); NIM-881 (Novartis); ISIS 14803™ (ISIS Pharmaceuticals, Carlsbad, Calif.); Heptazyme™ (Ribozyme Pharmaceuticals, Boulder, Colo.); Thymosin™ (SciClone Pharmaceuticals, San Mateo, Calif.); Maxamine™ (Maxim Pharmaceuticals, San Diego, Calif.); NKB-122 (JenKen Bioscience Inc., North Carolina); Alinia (Romark Laboratories), INFORM-1 (a combination of R7128 and ITMN-191); and mycophenolate mofetil (Hoffman-LaRoche, Nutley, N.J.).
The doses and dosage regimen of the other agents used in the combination therapies of the present invention for the treatment or prevention of HCV infection can be determined by the attending clinician, taking into consideration the approved doses and dosage regimen in the package insert; the age, sex and general health of the patient; and the type and severity of the viral infection or related disease or disorder. When administered in combination, the Silyl-Containing Heterocyclic Compound(s) and the other agent(s) can be administered simultaneously (i.e., in the same composition or in separate compositions one right after the other) or sequentially. This particularly useful when the components of the combination are given on different dosing schedules, e.g., one component is administered once daily and another component is administered every six hours, or when the preferred pharmaceutical compositions are different, e.g., one is a tablet and one is a capsule. A kit comprising the separate dosage forms is therefore advantageous.
Generally, a total daily dosage of the at least one Silyl-Containing Heterocyclic Compound(s) alone, or when administered as combination therapy, can range from about 1 to about 2500 mg per day, although variations will necessarily occur depending on the target of therapy, the patient and the route of administration. In one embodiment, the dosage is from about 10 to about 1000 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 1 to about 500 mg/day, administered in a single dose or in 2-4 divided doses. In still another embodiment, the dosage is from about 1 to about 100 mg/day, administered in a single dose or in 2-4 divided doses. In yet another embodiment, the dosage is from about 1 to about 50 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 500 to about 1500 mg/day, administered in a single dose or in 2-4 divided doses. In still another embodiment, the dosage is from about 500 to about 1000 mg/day, administered in a single dose or in 2-4 divided doses. In yet another embodiment, the dosage is from about 100 to about 500 mg/day, administered in a single dose or in 2-4 divided doses.
In one embodiment, when the additional therapeutic agent is INTRON-A interferon alpha 2b (commercially available from Schering-Plough Corp.), this agent is administered by subcutaneous injection at 3MIU (12 mcg)/0.5 mL/TIW for 24 weeks or 48 weeks for first time treatment.
In another embodiment, when the additional therapeutic agent is PEG-INTRON interferon alpha 2b pegylated (commercially available from Schering-Plough Corp.), this agent is administered by subcutaneous injection at 1.5 mcg/kg/week, within a range of 40 to 150 mcg/week, for at least 24 weeks.
In another embodiment, when the additional therapeutic agent is ROFERON A interferon alpha 2a (commercially available from Hoffmann-La Roche), this agent is administered by subcutaneous or intramuscular injection at 3MIU (11.1 mcg/mL)/TIW for at least 48 to 52 weeks, or alternatively 6MIU/TIW for 12 weeks followed by 3MIU/TIW for 36 weeks.
In still another embodiment, when the additional therapeutic agent is PEGASUS interferon alpha 2a pegylated (commercially available from Hoffmann-La Roche), this agent is administered by subcutaneous injection at 180 mcg/1 mL or 180 mcg/0.5 mL, once a week for at least 24 weeks.
In yet another embodiment, when the additional therapeutic agent is INFERGEN interferon alphacon-1 (commercially available from Amgen), this agent is administered by subcutaneous injection at 9 mcg/TIW is 24 weeks for first time treatment and up to 15 mcg/TIW for 24 weeks for non-responsive or relapse treatment.
In a further embodiment, when the additional therapeutic agent is Ribavirin (commercially available as REBETOL ribavirin from Schering-Plough or COPEGUS ribavirin from Hoffmann-La Roche), this agent is administered at a daily dosage of from about 600 to about 1400 mg/day for at least 24 weeks.
In one embodiment, one or more compounds of the present invention are administered with one or more additional therapeutic agents selected from: an interferon, an immunomodulator, a viral replication inhibitor, an antisense agent, a therapeutic vaccine, a viral polymerase inhibitor, a nucleoside inhibitor, a viral protease inhibitor, a viral helicase inhibitor, a viral polymerase inhibitor a virion production inhibitor, a viral entry inhibitor, a viral assembly inhibitor, an antibody therapy (monoclonal or polyclonal), and any agent useful for treating an RNA-dependent polymerase-related disorder.
In another embodiment, one or more compounds of the present invention are administered with one or more additional therapeutic agents selected from an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV replication inhibitor, a nucleoside, an interferon, a pegylated interferon and ribavirin. The combination therapies can include any combination of these additional therapeutic agents.
In another embodiment, one or more compounds of the present invention are administered with one additional therapeutic agent selected from an HCV protease inhibitor, an interferon, a pegylated interferon and ribavirin.
In still another embodiment, one or more compounds of the present invention are administered with two additional therapeutic agents selected from an HCV protease inhibitor, an HCV replication inhibitor, a nucleoside, an interferon, a pegylated interferon and ribavirin.
In another embodiment, one or more compounds of the present invention are administered with an HCV protease inhibitor and ribavirin. In another specific embodiment, one or more compounds of the present invention are administered with a pegylated interferon and ribavirin.
In another embodiment, one or more compounds of the present invention are administered with three additional therapeutic agents selected from an HCV protease inhibitor, an HCV replication inhibitor, a nucleoside, an interferon, a pegylated interferon and ribavirin.
In one embodiment, one or more compounds of the present invention are administered with one or more additional therapeutic agents selected from an HCV polymerase inhibitor, a viral protease inhibitor, an interferon, and a viral replication inhibitor. In another embodiment, one or more compounds of the present invention are administered with one or more additional therapeutic agents selected from an HCV polymerase inhibitor, a viral protease inhibitor, an interferon, and a viral replication inhibitor. In another embodiment, one or more compounds of the present invention are administered with one or more additional therapeutic agents selected from an HCV polymerase inhibitor, a viral protease inhibitor, an interferon, and ribavirin.
In one embodiment, one or more compounds of the present invention are administered with one additional therapeutic agent selected from an HCV polymerase inhibitor, a viral protease inhibitor, an interferon, and a viral replication inhibitor. In another embodiment, one or more compounds of the present invention are administered with ribavirin.
In one embodiment, one or more compounds of the present invention are administered with two additional therapeutic agents selected from an HCV polymerase inhibitor, a viral protease inhibitor, an interferon, and a viral replication inhibitor.
In another embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and another therapeutic agent.
In another embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and another therapeutic agent, wherein the additional therapeutic agent is selected from an HCV polymerase inhibitor, a viral protease inhibitor, and a viral replication inhibitor.
In still another embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and a viral protease inhibitor.
In another embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and an HCV protease inhibitor.
In another embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and boceprevir or telaprevir.
In a further embodiment, one or more compounds of the present invention are administered with ribavirin, interferon and an HCV polymerase inhibitor.
In another embodiment, one or more compounds of the present invention are administered with pegylated-interferon alpha and ribavirin.
Due to their activity, the Silyl-Containing Heterocyclic Compounds are useful in veterinary and human medicine. As described above, the Silyl-Containing Heterocyclic Compounds are useful for treating or preventing HCV infection in a patient in need thereof.
When administered to a patient, the Silyl-Containing Heterocyclic Compounds can be administered as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle. The present invention provides pharmaceutical compositions comprising an effective amount of at least one Silyl-Containing Heterocyclic Compound and a pharmaceutically acceptable carrier. In the pharmaceutical compositions and methods of the present invention, the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e., oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. Powders and tablets may be comprised of from about 0.5 to about 95 percent inventive composition. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate.
Liquid form preparations include solutions, suspensions and emulsions and may include water or water-propylene glycol solutions for parenteral injection.
Liquid form preparations may also include solutions for intranasal administration.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize therapeutic effects, i.e., antiviral activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
In one embodiment, the one or more Silyl-Containing Heterocyclic Compounds are administered orally.
In another embodiment, the one or more Silyl-Containing Heterocyclic Compounds are administered intravenously.
In one embodiment, a pharmaceutical preparation comprising at least one Silyl-Containing Heterocyclic Compound is in unit dosage form. In such form, the preparation is subdivided into unit doses containing effective amounts of the active components.
Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present compositions can contain, in one embodiment, from about 0.1% to about 99% of the Silyl-Containing Heterocyclic Compound(s) by weight or volume. In various embodiments, the present compositions can contain, in one embodiment, from about 1% to about 70% or from about 5% to about 60% of the Silyl-Containing Heterocyclic Compound(s) by weight or volume.
The quantity of Silyl-Containing Heterocyclic Compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 2500 mg. In various embodiment, the quantity is from about 10 mg to about 1000 mg, 1 mg to about 500 mg, 1 mg to about 100 mg, and 1 mg to about 100 mg.
For convenience, the total daily dosage may be divided and administered in portions during the day if desired. In one embodiment, the daily dosage is administered in one portion. In another embodiment, the total daily dosage is administered in two divided doses over a 24 hour period. In another embodiment, the total daily dosage is administered in three divided doses over a 24 hour period. In still another embodiment, the total daily dosage is administered in four divided doses over a 24 hour period.
The amount and frequency of administration of the Silyl-Containing Heterocyclic Compounds will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. Generally, a total daily dosage of the Silyl-Containing Heterocyclic Compounds range from about 0.1 to about 2000 mg per day, although variations will necessarily occur depending on the target of therapy, the patient and the route of administration. In one embodiment, the dosage is from about 1 to about 200 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 10 to about 2000 mg/day, administered in a single dose or in 2-4 divided doses. In another embodiment, the dosage is from about 100 to about 2000 mg/day, administered in a single dose or in 2-4 divided doses. In still another embodiment, the dosage is from about 500 to about 2000 mg/day, administered in a single dose or in 2-4 divided doses.
The compositions of the invention can further comprise one or more additional therapeutic agents, selected from those listed above herein. Accordingly, in one embodiment, the present invention provides compositions comprising: (i) at least one Silyl-Containing Heterocyclic Compound or a pharmaceutically acceptable salt thereof; (ii) one or more additional therapeutic agents that are not a Silyl-Containing Heterocyclic Compound; and (iii) a pharmaceutically acceptable carrier, wherein the amounts in the composition are together effective to treat HCV infection.
In one embodiment, the present invention provides compositions comprising a Compound of Formula (I) and a pharmaceutically acceptable carrier.
In another embodiment, the present invention provides compositions comprising a Compound of Formula (I), a pharmaceutically acceptable carrier, and a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
In another embodiment, the present invention provides compositions comprising a Compound of Formula (I), a pharmaceutically acceptable carrier, and two additional therapeutic agents, each of which are independently selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
In one aspect, the present invention provides a kit comprising a therapeutically effective amount of at least one Silyl-Containing Heterocyclic Compound, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
In another aspect the present invention provides a kit comprising an amount of at least one Silyl-Containing Heterocyclic Compound, or a pharmaceutically acceptable salt, solvate, ester or prodrug of said compound and an amount of at least one additional therapeutic agent listed above, wherein the amounts of the two or more active ingredients result in a desired therapeutic effect. In one embodiment, the one or more Silyl-Containing Heterocyclic Compounds and the one or more additional therapeutic agents are provided in the same container. In one embodiment, the one or more Silyl-Containing Heterocyclic Compounds and the one or more additional therapeutic agents are provided in separate containers.
Solvents, reagents, and intermediates that are commercially available were used as received. Reagents and intermediates that are not commercially available were prepared in the manner as described below. 1H NMR spectra were obtained on a Bruker Avance 500 (500 MHz) and are reported as ppm downfield from Me4Si with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33 mm×7 mm ID; gradient flow: 0 minutes—10% CH3CN, 5 minutes—95% CH3CN, 5-7 minutes—95% CH3CN, 7 minutes—stop. The retention time and observed parent ion are given. Flash column chromatography was performed using pre-packed normal phase silica from Biotage, Inc. or bulk silica from Fisher Scientific. Unless otherwise indicated, column chromatography was performed using a gradient elution of hexanes/ethyl acetate, from 100% hexanes to 100% ethyl acetate.
To a solution of L-valine (10.0 g, 85.3 mmol) in 1M aqueous NaOH solution (86 mL) at room temperature was added solid sodium carbonate (4.60 g, 43.4 mmol). The reaction mixture was cooled to 0° C. (ice bath) and then methyl chloroformate (7.20 mL, 93.6 mmol) was added dropwise over 20 minutes. The reaction mixture was then allowed to warm to room temperature, and allowed to stir at room temperature for an additional 4 hours. The reaction mixture was then diluted with diethyl ether (100 mL), the resulting solution was cooled to at 0° C., and then concentrated hydrochloric acid (18 mL, 216 mmol) was added slowly. The reaction was extracted with EtOAc (3×100 mL) and the combined organics were dried over MgSO4, filtered and concentrated in vacuo to provide Compound Int-1a (13.5 g, 90%), which was used without further purification.
The following intermediates can be prepared by the reaction of L-valine with isopropyl chloroformate (Aldrich Inc.), 2-methoxyethyl chloroformate (Aldrich) or with 1-methylcyclopropyl hydroxysuccinimide respectively, using the method described above:
To a solution of D-phenylglycine (10.0 g, 66.1 mmol) and NaOH (21.2 g, 265 mmol) in water (60 mL) at 0° C. was added methyl chloroformate (10.2 mL, 133 mmol) dropwise over 20 minutes. The resulting mixture was allowed to stir at 0° C. for 1 hour, then was acidified using concentrated hydrochloric acid (25 mL, 300 mmol). The acidic solution was extracted with EtOAc (3×100 mL) and the combined organics were dried over MgSO4, filtered and concentrated in vacuo to provide Compound Int-2a (12.6 g, 91%), which was used without further purification.
The following intermediates can be prepared by the reaction of glycine, L-Alanine and 4-F phenylglycine, respectively with methyl chloroformate (Aldrich Inc.) using the method described above:
A solution of D-phenylglycine (20.0 g, 132 mmol), 37% aqueous formaldehyde (66 mL, 814 mmol) and 5% Pd on carbon (8.0 g, mmol) in a mixture of methanol (80 mL) and 1 N HCl (60 mL) was placed on a hydrogenation shaker and shook under an atmosphere of 35-40 psi hydrogen for 4 hours. The reaction was then flushed with nitrogen, filtered through a celite pad and concentrated in vacuo to provide Compound Int-3a (29.7 g, quant.) as a white solid, which was used without further purification.
To a solution of methyl 2-(benzyloxycarbonylamino)-2-(dimethoxyphosphoryl)acetate (10.0 g, 30.2 mmol, made as described in Hamada et al., Organic Letters; English; 20: 4664-4667 (2009)) in THF (100 mL) at −20° C. was added tetramethylguanidine (4.20 mL, 33.2 mmol). The reaction mixture was allowed to stir at −20° C. for 1 hour then a solution of compound Int-4a (3.1 mL, 33.2 mmol) in THF (5 mL) was added and the reaction mixture was warmed to room temperature and stirred for about 15 hours. EtOAc (200 mL) was added and the organic mixture was washed with water (3×50 mL) and brine (50 mL). The organic layers were combined and dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified using flash chromatography on an ISCO 330 g Redi-Sep column using 0-35% EtOAc/hexanes as the eluent to provide Compound Int-4b as a white solid (615 mg, 45%). 1H NMR (CDCl3) δ 7.40-7.30 (m, 5H), 6.00 (br s, 1H), 5.12 (s, 2H), 3.80-3.65 (m, 7H), 2.92 (m, 2H), 2.52-2.48 (m, 2H).
To a solution of Int-4b (2.43 g, 7.96 mmol) in methanol (160 mL) previously purged with N2 was added (−)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane (cyclooctadiene)rhodium(I) tetrafluoroborate (487 mg, 0.880 mmol) under N2. The mixture was shaken in a Parr shaker apparatus for 18 hours at 50 psi of H2. After evacuating the hydrogen, the suspension was filtered and the filtrate was concentrated to provide Compound Int-4c as a white solid (1.30 g, 53%). 1H NMR (CDCl3) δ 7.40-7.30 (m, 5H), 5.32 (br s, 1H), 5.12 (s, 2H), 4.40-4.30 (m, 1H), 4.00-3.95 (m, 2H), 3.75 (s, 3H), 3.40-3.25 (m, 2H), 2.10-1.95 (m, 1H), 1.50-1.45 (m, 4H).
To a suspension of 50% palladium on carbon (10% wet, 200 mg) in absolute ethanol (20 mL) under nitrogen was added Int-4c (1.06 g, 3.45 mmol). With stirring, the solution was placed in vacuo for 30 seconds and then was opened to a hydrogen gas balloon for 2 hours. After evacuating the hydrogen, the suspension was filtered through a Celite pad and the pad washed with ethanol (2×20 mL). The filtrate was concentrated to provide a colorless oil (585 mg, 98%). 1H NMR (CDCl3) δ 4.06-3.96 (m, 2H), 3.73 (s, 3H), 3.48-3.28 (m, 3H), 1.92-1.78 (m, 1H), 1.61-1.47 (m, 6H).
To a solution of the colorless oil (585 mg, 3.37 mmol) and triethylamine (0.710 mL, 5.09 mmol) in CH2Cl2 (6 mL) was added methyl chloroformate (0.290 mL, 3.76 mmol). The reaction mixture was allowed to stir at room temperature for about 15 hours. Water (15 mL) was added and the aqueous mixture was extracted with CH2Cl2 (3×20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified using flash chromatography on an ISCO 24 g Redi-Sep column using 0-3% MeOH/CH2Cl2 as the eluent to provide Compound Int-4d as a colorless oil (600 mg, 77%). 1H NMR (CDCl3) δ 5.27-5.18 (m, 1H), 4.38-4.28 (m, 1H), 4.06-3.96 (m, 2H), 3.75 (s, 3H), 3.69 (s, 3H), 3.39-3.30 (m, 2H), 2.09-1.94 (m, 1H), 1.59-1.48 (m, 4H).
To a solution of compound Int-4d (600 mg, 2.59 mmol) in THF (5 mL) was added lithium hydroxide monohydrate (218 mg, 5.19 mmol) in water (5 mL). The reaction mixture was allowed to stir at room temperature for 2 hours then concentrated to half volume. The aqueous mixture was then acidified with 6N HCl and extracted with EtOAc (7×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to provide Compound Int-4e as an off-white solid (485 mg, 86%). 1H NMR (CD3OD) δ 4.09-4.07 (m, 1H), 3.96-3.92 (m, 2H), 3.65 (s, 3H), 3.40-3.34 (m, 2H), 2.10-1.99 (m, 1H), 1.56-1.47 (m, 4H).
A stirred mixture of Int-5a (50.0 g, 0.412 mol), ethyl glyoxylate (81.5 mL, 50% in toluene, 0.412 mol) and PPTS (0.50 g, 2.00 mmol) in benzene (600 mL) was heated to reflux in a Dean-Stark apparatus until no further water (˜8 mL) azeotroped from the reaction (˜4 h). The resulting mixture was concentrated in vacuo. The crude residue Int-5b was used without purification: 1H NMR (300 MHz, CDCl3) δ 7.72 (s, 1H), 7.36-7.24 (m, 5H), 4.61 (q, J=6.9 Hz, 1H), 4.35 (q, J=7.2 Hz, 2H), 1.62 (d, J=6.6 Hz, 3H), 1.34 (t, J=7.2 Hz, 311).
To a stirred solution of crude Int-5b in methylene chloride (600 mL) at −78° C. were added the following in 10 minute intervals: TFA (31.0 mL, 0.416 mol), boron trifluoride etherate (51.3 mL, 0.416 mol) and freshly distilled cyclopentadiene (32.7 g, 0.494 mol). After less than 2 minutes the reaction forms a thick brown mass. After 6 hours at −78° C. the reaction was allowed to slowly warm to room temperature for about 15 hours, at which time the reaction had formed a dark brown solution. The reaction was quenched with saturated aqueous Na2CO3 (˜900 mL) and stirred for 30 minutes. The resultant solids were removed by filtration through Celite®. The aqueous filtrate was extracted with methylene chloride (3×100 mL). The combined extracts were washed with saturated aqueous NaCl (2×75 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified using flash column chromatography (silica; 8×18 cm) using 10% to 25% ethyl acetate/hexanes as the eluent to provide endo Int-5c (10.9 g, 9%) as a brown oil: 1H NMR (300 MHz, CDCl3) δ 7.34-7.19 (m, 5H), 6.00-5.95 (m, 1H), 4.18 (q, J=7.1 Hz, 3H), 3.47 (s, 1H), 3.03 (s, 1H), 2.97 (q, J=6.5 Hz, 1H), 2.41 (s, 1H), 1.86 (d, J=8.2 Hz, 1H), 1.26 (t, J=6.6 Hz, 3H), 1.17 (t, J=6.6 Hz, 3H). Exo Int-6c (84.3 g, 74%) was collected as a brown oil: 1H NMR (300 MHz, CDCl3) δ 7.34-7.19 (m, 5H), 6.36-6.33 (m, 1H), 6.22-6.18 (m, 1H), 4.37 (s, 1H), 3.87 (q, J=6.8 Hz, 2H), 3.10 (q, J=6.5 Hz, 1H), 2.96 (s, 1H), 2.27 (s, 1H), 2.20 (d, J=8.4 Hz, 1H), 1.48 (d, J=6.5 Hz, 3H), 1.01 (d, J=7.0 Hz, 3H), 1.00 (m, 1H).
A mixture of exo-Int-5c (15.8 g, 0.582 mol) and 10% Pd/C (4.07 g, 50% wet) in a 1:2 mixture of EtOH/EtOAc (150 mL) was shaken in a Parr hydrogenation apparatus under an atmosphere of H2 (50 psi). After 23 hours the mixture was filtered through Celite® and the filtrate concentrated in vacuo. 1H NMR analysis of the resulting residue (10.8 g) showed some aromatic resonances present. Repetition of the hydrogenation procedure using 10% Pd/C (2.0 g) afforded Int-5d (10.0 g, quant.) as a brown oil: 1H NMR (300 MHz, CDCl3) δ 4.18 (q, J=7.2 Hz, 3H), 3.54 (s, 1H), 3.32 (s, 1H), 2.62 (s, 1H), 2.23 (s, 1H), 1.64-1.39 (m, 5H), 1.31-1.20 (m, 4H).
To a stirred mixture of Int-5d (36.6 g, 0.236 mol) and saturated aqueous Na2CO3 (300 mL) in THF (600 mL) at 0° C. was added di-tert-butyl dicarbonate (59.0 g, 0.270 mol). The reaction mixture was allowed to slowly warm to room temperature over 6 hours. After 68 hours the reaction mixture was diluted with EtOAc (250 mL) and water (250 mL). The aqueous layer was extracted with EtOAc (2×200 mL) and the combined extracts were washed with saturated aqueous NaCl (2×75 mL), dried over Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified using flash column chromatography (silica; 16×10 cm) using 10-20% ethyl acetate/hexanes as the eluent to provide Compound Int-5e (49.0 g, 84%) as a pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 4.35 (s, 0.6H), 4.22-4.10 (m, 2.4H), 3.81 (s, 0.45H), 3.71 (s, 0.55H), 2.66 (s, 1H), 1.96-1.90 (m, 1H), 1.76-1.50 (m, 3H), 1.55-1.45 (m, 5H), 1.39 (s, 5H), 1.30-1.23 (m, 4H).
To a stirred mixture of Int-5e (49.0 g, 0.182 mmol) in 1:1 THF/water (600 mL) was added LiOH.H2O (15.3 g, 0.364 mol). The reaction mixture was warmed to 60° C. for 47 hours, cooled to room temperature and concentrated in vacuo to remove excess THF. The resulting residue was diluted with CH2Cl2 (200 mL) then acidified with 2N HCl until pH˜4. The aqueous layer was extracted with CH2Cl2 (4×100 mL) and the combined extracts were washed with saturated aqueous NaCl (25 mL), dried over Na2SO4, filtered and concentrated in vacuo to provide Compound Int-5f (41.2 g, 93%) as an off white solid: 1H NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 4.13 (s, 0.56H), 4.06 (s, 0.47H), 3.61 (d, J=4.0 Hz, 1H), 2.59 (s, 1H), 1.75-1.45 (m, 5H), 1.39 (s, 4H), 1.32 (s, 5H), 1.23 (t, J=8.4 Hz, 1H); Optical Rotation: [α]D25-169.0° (c=1.1, CHCl3).
A 5 L-3 necked round bottomed flask, equipped with a mechanical stirrer, temperature probe, addition funnel and N2 inlet, was charged with the Schollkopf chiral auxiliary-(Int-6a, 200 g, 1.09 mol, 1.0 eq), bis(chloromethyl)dimethylsilane (Int-6b, 256 g, 1.63 mol, 1.5 eq), and THF (2 L, Aldrich anhydrous). The flask was cooled in a dry ice/2-propanol bath until the internal temperature reached −75° C. n-Butyl lithium (Aldrich 2.5 M in hexanes, 478 mL, 1.19 mol, 1.09 eq) was added via a dropping funnel over 1 hour while maintaining the internal reaction temperature between −67° C. and −76° C. The resulting orange-red solution was allowed to gradually warm to room temperature for about 15 hours. The reaction mixture was then re-cooled to 0° C. and quenched with 500 mL of water. Diethyl ether (2 L) was added and the layers were separated. The aqueous layer was extracted with 1 L of diethyl ether. The combined organic layers was washed with water and brine, dried with MgSO4, filtered, and concentrated in vacuo to provide 480 g of an orange oil. This material was left in vacuo for about 15 hours to provide 420 g of oil (mixture of Int-6c and Int-6c′). The crude product was split into two batches and purified via silica gel chromatography on a 1.6 Kg flash column. The column was eluted with gradient of 0-4% Et2O in hexanes. The product fractions were concentrated in vacuo at a bath temperature at or below 40° C. to provide 190 grams of Compound Int-6c (60% yield).
A 5 L, 3-necked round bottomed flask equipped with a mechanical stirrer, addition funnel, temperature probe, external water bath and N2 inlet was charged with compound Int-6c (196 g, 0.643 mol, 1.0 eq) and methanol (1.5 L). Aqueous HCl (500 mL of 10% by volume) was added at room temperature over 30 minutes, with a mild exotherm observed. The temperature increased to 37° C. then dropped back down. The reaction mixture was allowed to stir at room temperature for 3 hours and was monitored by TLC and LCMS. The reaction mixture was then concentrated in vacuo to an oil. Additional methanol (3×200 mL) was added and the reaction mixture was concentrated in vacuo again. The resulting crude product was dried under house vacuum for about 15 hours. The crude product was then dissolved in CH2Cl2 (750 mL) and Et2O (1250 mL) and sodium iodide (96.4 g, 0.643 mol, 1.0 eq) was added. Diisopropylethylamine (336 mL, 1.929 mol, 3.0 eq) was added slowly over 25 minutes with efficient stirring, causing the temperature to increase to 35° C. then decrease again. The reaction mixture was allowed to stir at room temperature for 2 hours, at which time the MS of an aliquot indicated consumption of the starting material. The reaction mixture was allowed to stir for an additional 2 hours and then Boc-anhydride (281 g, 1.286 mol, 2.0 eq) was added. The reaction mixture was then allowed to stir at room temperature/. After two days, the reaction mixture was diluted with EtOAc (2 L) and water (1 L), and he layers were separated. The aqueous phase was extracted with 500 mL of EtOAc. The combined organic layers were washed with water (500 mL), and brine (500 mL), dried with MgSO4, filtered, and concentrated in vacuo to a yellow oil (380 g). The crude product was split into two 180 g portions for convenience and each portion was purified via flash silica gel chromatography. Column conditions for a 180 g portion of crude product are as follows. The 180 gram sample of crude product was loaded onto a 191 g SiO2 cartridge and purified on a 1.5 Kg SiO2 column. The column was eluted using a 0%-20% EtOAc/hexanes gradient as the mobile phase to provide 52 grams of pure Int-6d and additional fractions of Int-6d that contained a small amount of a Boc-valine impurity. The impure fractions from the two columns were recombined and re-purified. After chromatography, compound Int-6d was obtained as an oil which solidified to a white solid on standing (128 g, 65% yield over the three steps.)
A solution of Int-6d (8.5 g, 31.1 mmol) in methanol (100 mL) and 1.0 M aqueous KOH solution (48 mL, 48 mmol) was allowed to stir at room temperature for about 15 hours, neutralized with 48 mL of 1.0 M aqueous HCl solution to pH˜5, and concentrated in vacuo to an oil. The resulting residue was extracted with dichloromethane (2×100 mL) and the combined organic layers were concentrated in vacuo to provide Compound Int-6e as a gel (7.74 g, 96%). Chiral purity was determined using a Chiralcell AD-H column, SFC mode, CO2/MeOH 90/10.
Mercuric acetate (14.3 g, 44.8 mmol) was dissolved in water (45 mL), and THF (45 mL) was added. To this yellow solution at room temperature was added (chloromethyl)-dimethylvinylsilane (5.65 g, 41.9 mmol) which became homogeneous in 30 seconds. The resulting solution was allowed to stir for 5 minutes, then aqueous NaOH (3M, 45 mL) was added, followed by a solution (45 mL) of NaBH4 (0.5M) in 3M NaOH. Diethyl ether (160 mL) was added and the mixture stirred at room temperature for and additional 1 hr. The mixture was then saturated with NaCl and the layers separated. The organic layer was washed with brine (100 mL), dried with Na2SO4, and concentrated in vacuo to provide Compound Int-7a as a colorless oil (5.72 g, 89%). 1H NMR (CDCl3) δ 3.84-3.75 (m, 2H), 2.81 (s, 2H), 1.34-1.31 (m, 1H), 1.10-1.05 (m, 2H), 0.148 (s, 6H).
To a solution of Int-7a (5.72 g, 37.4 mmol) in CH2Cl2 (50 mL) was added imidazole (3.82 g, 56.1 mmol). The mixture was allowed to stir at 0° C. and tert-butyldimethylsilyl chloride (8.46 g, 56.1 mmol) was slowly added over 10 minutes and the reaction mixture was warmed to room temperature and stirred for about 15 hours. Water (50 mL) was added and the layers separated. The aqueous layer was extracted with CH2Cl2 (3×30 mL) and the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo at 80° C. to remove residual tert-butyldimethylsilyl chloride and afford the desired product Int-7b as a colorless oil (9.82 g, 98%). 1H NMR (CDCl3) δ 3.75 (t, J=7.4 Hz, 2H), 2.78 (s, 2H), 0.99 (t, J=7.4 Hz, 2H), 0.87 (s, 9H), 0.011 (s, 6H), 0.02 (s, 6H).
To a solution of (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (6.16 g, 33.4 mmol) in THF (60 mL) was added TBAI (617 mg, 1.67 mmol). The mixture was cooled to −78° C. and a solution of n-BuLi (14.7 mL, 2.5M in hexanes, 36.75 mmol) was slowly added over 10 minutes. The reaction mixture was allowed to stir at −78° C. for 30 minutes, then Int-7b in THF (20 mL) was slowly added over 10 minutes. The reaction was allowed to stir at −78° C. for 2 hours then allowed to warmed to room temperature and stirred for about 15 hours. The reaction was quenched by addition of MeOH (5 mL), concentrated in vacuo, water added (50 mL) followed by diethyl ether (50 mL) and the layers were separated. The organic layer was washed with water (2×50 mL) then dried over Na2SO4, filtered and concentrated in vacuo to provide the crude product. Further purification by column chromatograpy on a 330 g ISCO Redi-Sep silica gel column using a eluent of CH2Cl2 with a gradient of 0-10% EtOAc/hexanes afforded the desired product Int-7c as a light amber oil (8.65 g, 63%). 1H NMR (CDCl3) δ 4.07-3.99 (m, 1H), 3.94-3.89 (m, 1H), 3.79-3.71 (m, 2H), 3.68-3.63 (m, 6H), 2.32-2.17 (m, 1H), 1.25-1.21 (m, 1H), 1.06-0.95 (m, 5H), 0.88 (s, 10H), 0.74-0.68 (m, 1H), 0.69-0.66 (m, 2H), 0.12-0.02 (m, 12H).
To a THF solution (60 mL) of Int-7c (8.65 g, 20.8 mmol) cooled to 0° C. was slowly added a solution of tetrabutylammonium fluoride (31.3 mL, 1.0M in THF, 31.0 mmol) over 5 minutes. The reaction mixture was allowed to warm to room temperature for about 15 hours with stirring. The reaction was then concentrated in vacuo, and the crude product chromatographed on a 120 g ISCO Redi-Sep silica gel column using a CH2Cl2 with gradient of 0-3% MeOH/CH2Cl2 as the eluent to provide Compound Int-7d as a colorless oil (4.69 g, 99%). 1H NMR (CDCl3) δ 4.15-4.05 (m, 1H), 3.98-3.91 (m, 1H), 3.84-3.73 (m, 2H), 3.69 (s, 6H), 2.39-2.32 (m, 1H), 2.30-2.18 (m, 1H), 1.37-1.29 (m, 1H), 1.10-1.01 (m, 5H), 0.93-0.85 (m, 2H), 0.74-0.68 (m, 2H), 0.14-0.08 (m, 6H).
To a Et2O (30 mL) solution of compound Int-7d (2.12 g, 267 mmol) was added pyridine (720 μL, 8.82 mmol). The mixture was cooled to 0° C. and thionyl chloride (575 μL, 7.90 mmol) in Et2O (2 mL) was slowly added over 5 minutes. The reaction mixture was allowed to warm to room temperature for about 15 hours with stirring. The reaction mixture was filtered and the filtrate concentrated in vacuo to provide the crude product. Further purification by column chromatography using a 80 g ISCO Redi-Sep silica gel column with CH2Cl2 and a gradient of 0-3% MeOH as the eluent provided compound Int-7e as an amber oil (417 mg, 16%). 1H NMR (CDCl3) δ 4.22-3.62 (m, 7H), 2.50-2.13 (m, 4H), 1.58-1.41 (m, 1H), 1.32-0.65 (m, 9H), 0.24-0.04 (m, 6H).
To a solution of Int-7e (417 mg, 1.40 mmol) in MeOH (10 mL) was added a 10% aqueous HCl solution (10 mL). The resulting mixture was allowed to stir at room temperature for about 15 hours and concentrated in vacuo. The resulting residue was coevaporated with MeOH (3×30 mL) and then dissolved in CH2Cl2 (3 mL) and Et2O (6 mL). To this solution was added diisopropylethylamine (750 μL, 4.30 mmol) and the reaction allowed to stir at room temperature After 7 hours di-tert-butyl dicarbonate (703 mg, 3.22 mmol) was added and the reaction was allowed to stir for about 15 hours at room temperature and then concentrated in vacuo. The crude product was further purified using column chromatographed using a 12 g ISCO Redi-Sep silica gel column with CH2Cl2 and gradient of 0-50% EtOAc/hexanes mixture as the eluent to provide Compound Int-7f as an amber oil (94 mg, 23%). 1H NMR (CDCl3) δ 4.22-4.01 (m, 1H), 4.10-3.94 (m, 1H), 3.85-3.70 (m, 3H), 2.32-2.09 (m, 1H), 1.44 (s, 7H), 1.24-0.88 (m, 6H), 0.16-0.05 (m, 6H).
To a solution of compound Int-7f (218 mg, 0.758 mmol) in THF (3 mL) was added lithium hydroxide monohydrate (64 mg, 1.52 mmol) in water (3 mL). The reaction mixture was allowed to stir at room temperature for about 15 hours then concentrated in vacuo to half volume. The aqueous mixture was then acidified with 1N HCl to pH 4 and extracted with EtOAc (5×30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to provide Compound Int-7g as an off-white solid (157 mg, 87%). 1H NMR (CDCl3) δ1.44 (s, 8H), 1.34-0.78 (m, 9H), 0.17-0.03 (m, 6H).
Bis(chloromethyl)dimethylsilane (Int-8a, 50 g, 0.32 mol), sodium iodide (181 g, 1.21 mol), and dried acetone (1 liter) were added to a 2-liter round-bottomed flask. The resulting suspension was refluxed with stirring for 3.5 hours before cooled to room temperature. After filtration, the filtrate was concentrated and the residue obtained was treated with ethyl acetate (500 mL). The suspension was filtered again and the residue obtained was concentrated in vacuo to provide Int-8b as an oil (90.5 g, 84%). This material was pure enough for the next reaction.
(R)-2,5-Dihydro-3,6-dimethoxy-2-isopropylpyrazine (Int-8c, 25 g, 135.7 mmol) and dried THF (500 mL) were added to a dried 1-liter flask which was cooled to −78° C. and maintained under nitrogen atmosphere. A solution of 2.5 M n-BuLi in hexane (54 mL, 135 mmol) was added slowly via a syringe. The resulting solution was allowed to stir at the cold temperature for 30 min before addition of Int-8b (90.5 g, 266.2 mmol) via a syringe. The reaction mixture was continued to stir for 4 hours and warmed to room temperature gradually over a period of 1 hour. After addition of water (100 mL) and diethyl ether (1.0 liter), the solution was washed with water (2×200 mL) and dried over sodium sulfate. The solution was concentrated and the residue obtained was purified using a 330 g ISCO silica column on Combi-Flash with 0-1% ether in hexanes as an eluent to provide Int-8d as an oil (18.5 g, 35%).
The intermediate material Int-8d (18.5 g, 46.7 mmol) was dissolved in methanol (105 mL) in a 500 mL flask. 35 mL of 10% aqueous HCl solution was added slowly. The resulting mixture was allowed to stir at room temperature for 5 hours and concentrated to dryness. The residue obtained was co-evaporated 4 times with methanol (120 mL) and then dissolved in dichloromethane (80 mL) and diethyl ether (120 mL). To this solution was added N,N-diisopropylethylamine (18 mL, 135 mmol). The reaction mixture was allowed to stir at room temperature for 7 hours prior to addition of di-tert-butyl dicarbonate (23.5 g, 108 mmol). The solution was continued to stir at room temperature for about 15 hours and concentrated in vacuo. The residue obtained was taken up with ethyl acetate (300 mL), washed with water (200 mL), dried over sodium sulfate, and concentrated again. The crude product was purified using a 330 g ISCO silica column with 0-20% ethyl acetate in hexanes to provide 5 as a colorless oil (8.5 g, 67%).
A solution of Int-8e (8.5 g, 31.1 mmol) in methanol (100 mL) and 1.0 M aqueous KOH solution (48 mL, 48 mmol) was allowed to stir at room temperature for about 15 hours, neutralized with 48 mL of 1.0 M aqueous HCl solution to PH˜5, and concentrated to dryness. The residue obtained was extracted with dichloromethane (2×100 mL). The combined organic solutions were concentrated in vacuo to provide 6 as a gel (7.74 g, 96%).
The starting materials Int-9a (9.0 g, 32.4 mmol) and Int-8f (7.74 g, 29.85 mmol) were dissolved in DMF (50 mL). Triethylamine (10 mL, 71.83 mmol) was added slowly at room temperature. The mixture was allowed to stir at this temperature for about 15 hours, diluted with ethyl acetate (500 mL), washed with brine (3×100 mL), dried over sodium sulfate, and concentrated in vacuo. The residue obtained was purified using a 220 g ISCO silica column with 0-20% ethyl acetate in hexanes as an eluent to provide Int-9b as a gel (12.3 g, 83%).
A mixture of Int-9b (12.3 g, 26.96 mmol), ammonium acetate (18.0 g, 233.68 mmol), and xylenes (50 mL) in a 350 mL pressure vessel was allowed to stir at 120° C. for two hours. After cooling to room temperature, the suspension was concentrated in vacuo. The residue obtained was dissolved in ethyl acetate (300 mL), washed with water (100 mL) and saturated sodium carbonate solution (100 mL), dried over sodium sulfate, and concentrated in vacuo. The residue obtained was then purified using a 330 g ISCO silica column with 10-50% ethyl acetate in hexanes as an eluent to provide Int-9c as a pale solid (8.5 g, 72%).
Intermediate Int-10a was prepared from the commercially available N-Boc-4,4-difluoro-L-proline (Aldrich) using the method described in Example 9.
Intermediate Int-11a was prepared from the commercially available N-Boc-trans-fluoro-L-proline (Alfa) using the method described in Example 9.
Intermediate Int-12a was prepared from the commercially available (1R,3S,4S)—N-Boc-2-azabicyclo[2.2.1]-heptane-3-carboxylic acid (Aldrich) using the method described in Example 9.
Intermediate Int-13a was prepared from commercially available N-Boc-L-proline (Aldrich) using the method described in Example 9.
Intermediate Int-14a was prepared from commercially available (1S,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (Wuxi Apptech Co.), using the method described in Example 9.
Intermediate Int-15a was prepared from BOC-HYP-OH, which is commercially available from Aldrich, using the method described in Example 9.
Intermediate Int-16a was prepared from 2(S)-azabicyclo[2.2.2]-octane-2,3-dicarboxylic acid 2-tert-butyl ester, which is commercially available from Wuxi Apptech Co., using the method described in Example 9.
Int-10a (5.7 g, 13.31 mmol), bis(pinacolaton)diboron (6.8 g, 26.78 mmol), tetrakis(triphenylphosphine) palladium (0) (0.76 g, 0.66 mmol), and potassium acetate (2.0 g, 20.37 mmol) were taken up in dioxane (130 mL). The resulting suspension was degassed and stirred at 80° C. for about 15 hours. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo. The resulting residue was purified using a 220 g ISCO silica column on Combi-Flash Rf with elution of 0-4% methanol in dichloromethane to provide Int-17a as a wax (5.4 g, 85%).
Intermediate Int-18a was prepared from intermediate bromide Int-11a using the method described in Example 17.
Intermediate Int-19a was prepared from intermediate bromide Int-12a using the method described in Example 17.
Intermediate Int-20a was prepared from intermediate bromide Int-13a using the method described in Example 17.
Intermediate Int-21a was prepared from intermediate bromide Int-14a using the method described in Example 17.
Intermediate Int-22a was prepared from intermediate bromide Int-15a using the method described in Example 17.
Intermediate Int-23a was prepared from intermediate bromide Int-16a using the method described in Example 17.
Intermediate Int-24a was prepared from intermediate bromide Int-9c using the method described in Example 17.
A solution of compound Int-25a (2.7 g, 11.4 mmol), compound Int-8f (2.2 g, 7.77 mmol), Hunig's base (2 mL, 15 mmol), and HATU (3.0 g, 7.89 mmol) was cooled to 0° C. and allowed to stir at this temperature for The resulting 6.5 hours. The reaction mixture was then diluted with water (150 mL) and filtered. The collected solid was purified using a 330 g ISCO silica column on Combi-Flash Rf with elution of 0-5% methanol in dichloromethane to provide compound Int-25b as a foam (3.55 g, 96%).
A mixture of compound Int-25b (2.0 g, 4.18 mmol) and acetic acid (20 mL) was allowed to stir at 60° C. for 5 hours and then cooled to room temperature. After evaporation of acetic acid in vacuo, the residue obtained was purified using a 120 g ISCO silica column on Combi-Flas RF with elution of 0-5% methanol in dichloromethane to provide compound Int-25c as a solid (1.56 g, 81%).
Intermediate compounds Int-25d to Int-25 g were prepared using the method above and substituting the appropriate reactants and/or reagents.
Intermediate compound Int-26a was prepared from commercially available 2(S)-azabicyclo[2.2.2]-octane-2,3-dicarboxylic acid 2-tert-butyl ester, using the method described in Example 25.
Compound Int-25e (1.6 g, 3.54 mmol), bis(pinacolaton)diboron (2.1 g, 8.27 mmol), tetrakis(triphenylphosphine) palladium (0) (0.2 g, 0.173 mmol), potassium acetate (0.5 g, 5.09 mmol) were added to a 250 mL flask. The resulting suspension was degassed and stirred at 80° C. for about 15 hours. After cooling to room temperature the mixture was filtered and the filtrate was concentrated in vacuo. The resulting residue was purified using a 120 g ISCO silica column on Combi-Flash Rf with elution of 0-4% methanol in dichloromethane to provide Int-27a as a wax (1.3 g, 74%).
The intermediates Int-27b to Int-27f were prepared using the method above and substituting the appropriate reactants and/or reagents.
Compound Int-27b (0.55 g, 1.19 mmol), Int-9c (0.35 g, 0.80 mmol), PdCl2dppf dichloromethane complex (65 mg, 0.08 mmol), a solution of sodium carbonate (1.5M, 1.0 mL, 1.5 mmol), and 1,4-dioxane (10 mL) were added to a 200 mL flask. The resulting mixture was degassed and refluxed under nitrogen atmosphere for about 15 hours. After cooled to room temperature and concentrated, the residue obtained was purified using an 80 g ISCO silica column on Combi-Flash Rf with 0-4% methanol in dichloromethane as an eluent to provide 1 as a pale foam (320 mg, 58%). LCMS anal. calcd. For: C39H48N6O4Si 692.4; Found: 693.4 (M+H)+.
Compound 1 (320 mg, 0.462 mmol) was dissolved in dichloromethane (3 mL) and trifluoroacetic acid (3 mL). The resulting solution was allowed to stir at room temperature for 5 hours and then concentrated in vacuo to provide compound 2 as a solid (225 mg), which was used for the next reaction without purification.
Diamine 2 (225 mg, ˜0.46 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (Int-28a, 200 mg, 1.14 mmol), Hunig's base (0.5 mL, 3.75 mmol), HATU (435 mg, 1.14 mmol), and DMF (5 mL) were added to a 100 mL flask at 0° C. The resulting solution was allowed to stir at room temperature for 2.5 hours. The purification of the reaction solution by Gilson reverse phase chromatography (0-90% acetonitrile in water with 0.1% TFA as an eluent) provided compound 3 as a white solid (180 mg, 49%). LC-MS anal. calcd. for: C43H54N8O6Si 806.4; Found: 807.4 (M+H)+.
Compounds 4-12, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
To a solution of compound Int-25c (1.66 g, 3.61 mmol), Int-20a (1.76 g, 4.01 mmol), and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.324 g, 0.397 mmol) in dioxane (24 mL) was added a solution of 1N potassium carbonate (10.82 mL, 10.82 mmol). The reaction was degassed and stirred at 80° C. for 16 hours. The reaction mixture was then cooled to room temperature and diluted with water and EtOAc. The organic layer was removed and the aqueous phase was extracted with EtOAc (2×). The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue obtained was purified using silica gel chromatography (120 g column, 0% to 5% MeOH/DCM (36 minutes)) to provide 16 (2.1 g, 3.03 mmol, 84% yield).
To a solution of compound 16 (0.10 g, 0.14 mmol) in CH2Cl2 (3 mL) under N2 was added TFA (1 mL) in one portion and the resultant solution was stirred under N2 at rt 1.5 hr. The mixture was concentrated to dryness and was treated with 4.0 M HCl/Dioxane (3 mL) for 30 min. The mixture was concentrated in vacuo and the residue obtained was further dried in vacuo to provide 90 mg (99%) of the tetrahydrochloride salt of compound 17. LC-MS=493.2.
To a solution of the tetrachloride salt of compound 17 (71 mg, 0.14 mmol) in DMF (1.5 mL) at −15° C. (acetone/ice bath) was added Int-4e (66 mg, 0.30 mmol) followed by HATU (0.115 g, 0.30 mmol). The mixture was stirred or 15 minutes, then DIPEA (0.13 mL, 0.72 mmol) was added dropwise and the resulting reaction was allowed to stir at −15° C. until the reaction was deemed to be complete by LCMS (˜90 min). The reaction was quenched by adding 3 mL H2O and 15 mL EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc (2×7 mL) and the combined organic extracts were washed with H2O (3×3 mL), brine (3×3 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The resulting residue was dissolved in DMF (3 mL) and was purified using reverse-phase HPLC using a C18 column (0% ACN to 90% ACN/10% with 0.1% TFA) to provide 85 mg (61%) of compound 18 as a light yellow solid. LC-MS=891.5.
Compounds 19 and 20, depicted in the table below, was prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
Using the method described above in Example 28, Step 3, compound 17 (69 mg, 0.11 mmol) was reacted with Int-30a (47 mg, 0.23 mmol) to provide 80 mg (73%) of compound 21 as its dihydrochloride salt after salt formation with HCl. LC-MS: 872.6.
A mixture of compound 17 (34 mg, 0.53 mmol), compound Int-31a (37 mg, 0.160 mmol), and DIEA (93 μL, 0.53 mmol) in a solution of 1:1 acetonitrile:THF (3.0 mL) was stirred in a capped vial at room temperature for 10 minutes. A 50% solution of 1-propanephosphonic acid cyclic anhydride in ethyl acetate (1.1 mL, 1.87 mmol) was then added and the reaction was allowed to stir for 3 hours. The reaction was then quenched with 1 mL of a 1:1 mixture of 4N HCl in dioxane: dichloromethane and stirred at room temperature for about 15 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified using reverse phase HPLC to provide 5.0 mg of compound 22, (11.3%, >99% purity) LC-MS=835.1
Compounds 23-34, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
A solution of compound 2 (25 mg, 0.051 mmol), compound Int-32a (31 mg, 0.153 mmol), DIEA (44.3 μl. 0.254 mmol) in acetonitrile (254 μl) and THF (254 μl) was agitated for 1 minute. 1-Propanephosphonic acid cyclic anhydride (45.3 μl, 0.152 mmol, 40% in EtOAc) was then added and agitation continued for 18 hours at room temperature. The reaction mixture was concentrated in vacuo, and the residue obtained was dissolved in 1 mL DMSO, filtered, and purified using reverse-phase LC to provide Compound 35 (6 mg, 0.007 mmol, 13.7% yield).
Compound 36-41, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
A solution of compound 2 (25 mg, 0.051 mmol), Int-37a (31 mg, 0.153 mmol) and DIEA (44.3 μl, 0.254 mmol) in acetonitrile (254 μl) and THF (254 μl) was agitated for 1 minute, followed by addition of 1-propanephosphonic acid cyclic anhydride (45.3 μl, 0.152 mmol, 40% in EtOAc). The resulting mixture was agitated for 18 hours at room temperature to provide crude 42.
4N HCl (0.2 mL) in dioxane was added into reaction mixture obtained in Step A and the resulting reaction was agitated for 3 hours. The reaction mixture was then concentrated in vacuo to provide compound 43 as a yellow syrup that was used without further purification.
Compound 43 was dissolved in THF (0.5 mL) and acetonitrile (0.5 mL) and to the resulting solution was added methyl chloroformate (25.8 mg, 0.273 mmol). The resulting reaction agitated for 18 hours. 4N HCl (0.2 mL) was added into mixture, agitated for 3 h at room temperature, and concentrated in vacuo. The residue obtained was dissolved in 1 mL DMSO, filtered and purified using reverse LC to provide compound 44 (12.1 mg, 0.0155 mmol, 30.4% overall yield).
Compounds 45-54, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
To a solution of compound Int-25c, compound Int-34a (3.15 g, 6.65 mmol), and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.500 g, 0.612 mmol) in dioxane (39 mL) was added a solution of 1N potassium carbonate (18.0 mL, 18.00 mmol). The reaction was degassed and stirred at 80° C. for 16 hours. The reaction was cooled to room temperature and diluted with water and EtOAc. The organic layer was removed and the aqueous phase was extracted with EtOAc (2×). The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The crude material was purified using silica gel chromatography (120 g column, 0% to 5% MeOH/DCM (36 minutes)) to provide compound 55 (1.90 g, 2.61 mmol, 44.6% yield).
A solution of compound 55 (500 mg, 0.688 mmol) and Pd/C (115 mg, 1.081 mmol) in acetic acid (10 mL) was degassed and stirred over hydrogen gas for 2 hours. The reaction was filtered through a pad of celite with the aid of DCM. The brown solution was brought to a pH˜9 with solid K2CO3 and the organic layer was removed. The aqueous phase was extracted with DCM (3×) and the combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue obtained (504 mg, 0.850 mmol), compound Int-34b (223 mg, 1.275 mmol), and DIEA (0.445 mL, 2.55 mmol) were then taken up in DCM (6 mL) and to the resulting solution was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (0.81 mL, 1.36 mmol). The reaction was allowed to stir at room temperature for 2 hours and then quenched with water. The organic layer was removed and the aqueous phase was extracted with DCM (3×). The combined organic extracted were dried (Na2SO4), filtered, and concentrated in vacuo and the residue obtained was purified using silica gel chromatography (40 g column, 0% to 5% MeOH/DCM (25 min)) to provide compound 56 (246 mg, 0.328 mmol, 38.6% yield).
A solution of compound 56 (664 mg, 0.913 mmol) and TFA (2 mL, 26.0 mmol) in DCM (8 mL) was allowed to stir at room temperature for 3 hours. The reaction was concentrated to remove as much TFA as possible. The brown oil was taken up in DCM and washed with saturated K2CO3 (3×). The combined organics were dried (Na2SO4), filtered and concentrated to provide compound 57 (510 mg, 0.814 mmol, 89% yield).
To a solution of compound 57 (25 mg, 0.038 mmol) and compound Int-34b (15.4 mg, 0.076 mmol) in acetonitrile (0.25 mL) and THF (0.25 mL) was added DIEA (20.2 uL, 0.115 mmol) and the resulting reaction was shaken for 1 minute. 1-propanephosphonic acid cyclic anhydride (34.4 μl, 0.115 mmol, 40% in EtOAc) was added and the reaction was agitated for 18 hours at room temperature. The reaction mixture was concentrated in vacuo and the residue obtained was dissolved in 1 mL DMSO, filtered and purified using reverse phase LC to provide compound 58 (5.9 mg, 0.007 mmol, 18.6% yield). LC-MS=834.0
Compounds 59-78, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
A solution of compound 55 (664 mg, 0.913 mmol) and TFA (2 mL, 26.0 mmol) in DCM (8 mL) was allowed to stir at room temperature for 3 hours. The reaction was concentrated in vacuo to remove as much TFA as possible and the resulting brown oily residue was taken up in DCM and washed with saturated K2CO3 (3×). The combined organics were dried (Na2SO4), filtered and concentrated in vacuo. The material was carried on without purification.
To a solution of crude material prepared above (510 mg, 0.814 mmol), compound Int-1a (214 mg, 1.220 mmol) and DIEA (0.426 mL, 2.441 mmol) in DCM (6 mL) was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (0.727 mL, 1.220 mmol). The reaction was allowed to stir at room temperature for 2 hours and then quenched with water. The organic layer was removed and the aqueous phase was extracted with DCM (3×). The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue obtained was purified using silica gel chromatography (40 g column, 0% to 5% MeOH/DCM (25 min)) to provide compound 79 (484 mg, 0.617 mmol, 76% yield).
A solution of compound 79 in acetic acid (5.8 mL) was degassed and stirred over hydrogen gas for 2 hours. The reaction was filtered through a pad of celite with the aid of DCM. The brown solution was brought to a pH˜9 with solid K2CO3 and the organic layer was removed. The aqueous phase was extracted with DCM (3×) and the combined organics were dried (Na2SO4), filtered, and concentrated to provide compound 80, which was used without further purification.
A mixture of compound 80 (16.7 mg, 0.026 mmol), compound Int-31a (7 mg, 0.038 mmol), and N-ethyl-N-isopropylpropan-2-amine (13.4 μL, 0.077 mmol) in a solution of 1:1:acetonitrile:thetrahydrofuan (1.0 mL) was stirred in a vial at room temperature for 10 minutes. To this mixture was added a 50% solution of 1-propanephosphonic acid cyclic anhydride in ethyl acetate. The capped vials were stirred at room temperature for 3 h. The resultant mixture was quenched with 1 mL of a 1:1 mixture of 4N HCl in dioxane: dichloromethane and stirred at room temperature for about 15 hours. The solvents were concentrated in vacuo and the resultant mixture was purified using reverse phase HPLC to provide 6.3 mg, (29.5%, >99% purity) of compound 81. C44H56N8O6Si MW 820.41; M+1=821 found.
Compounds 82-92, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
A solution of compound 46 (150 mg, 0.216 mmol) and NCS (36 mg, 0.270 mmol) in DMF (1.0 mL) was allowed to stir at 50° C. for 2 hours. The reaction was concentrated and the residue obtained was purified using silica gel chromatography (12 g column, 0% to 5% MeOH/DCM (12 minutes) to provide compound 93 (99 mg, 0.136 mmol, 62.9% yield).
A solution of compound 93 (99 mg, 0.136 mmol) in hydrochloric acid (1 mL, 4.00 mmol) in dioxane and methanol (0.5 mL) was allowed to stir for 3 hours at room temperature. The reaction was concentrated in vacuo and the resulting residue (82 mg, 0.156 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid Int-1a (68.1 mg, 0.389 mmol) and DIPEA (0.272 mL, 1.556 mmol) were taken up in a mixture of acetonitrile (0.5 mL) and THF (0.500 mL). To the resulting solution was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (0.232 mL, 0.389 mmol). The reaction was allowed to stir at room temperature for 90 minutes and then quenched with HCl (0.2 mL, 0.800 mmol) and stirred for 16 hours at room temperature. The reaction was concentrated and the residue obtained was purified using reverse phase chromatography (C18 Luna 21×100 mm, 10:90 to 100:00 CH3CN/H2O (10 min)) to provide compound 94 (74 mg, 0.085 mmol, 54.8% yield).
A solution of compound 1 (121 mg, 0.175 mmol) and NCS (30.3 mg, 0.227 mmol) in DMF (1.0 mL) was allowed to stir at 50° C. for 16 hours. The reaction was cooled to room temperature and diluted with water and DCM. The organic layer was removed and the aqueous phase was extracted with DCM (3×). The combined organics were concentrated and the residue obtained was purified using reverse phase chromatography (C18 Luna 5 micron, 10:90 to 100:00 CH3CN/H2O (10 minutes) to provide compound 95 (25 mg, 0.034 mmol, 20% yield).
A solution of compound 95 (29 mg, 0.040 mmol) in hydrochloric acid (0.5 mL, 2.000 mmol) in dioxane and methanol (0.5 mL) was allowed to stir for 16 hours at room temperature. The reaction was concentrated in vacuo and the resulting residue (18 mg, 0.034 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid Int-1a (22 mg, 0.126 mmol) and DIEA (0.080 mL, 0.458 mmol) were taken up in THF (0.400 mL) and acetonitrile (0.400 mL). To the resulting solution was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (0.080 mL, 0.134 mmol). The reaction was allowed to stir at room temperature for 90 minutes and then quenched with HCl (0.2 mL, 0.800 mmol) and stirred for 2 hours at room temperature. The reaction was concentrated and the residue obtained was purified using reverse phase chromatography (C18 Luna 21×100 mm, 10:90 to 100:00 CH3CN/H2O (10 min)) to provide compound 96 (11.8 mg, 0.012 mmol, 36.2% yield).
To a 100 mL round bottom flask charged with a stir bar was added compound Int-25c (0.54 g, 1.18 mmol), bis(pinacolato)diboron (0.33 g, 1.3 mmol), KOAc (0.35 g, 3.5 mmol), and PdCl2dppf CH2Cl2 (0.19 g, 0.24 mmol). Dioxane (7 mL) was added to the flask and a N2 line was inserted. Using the N2 line, the reaction mixture was degassed under house vacuum and filled with N2 five times. The tube was heated to 95° C. and stirred under N2 for 4 h whereupon the reaction was deemed to be complete by LC-MS. To the cooled flask containing the intermediate boronate was added bromo imidazole Int-38d (0.53 g, 1.3 mmol), PdCl2dppf.CH2Cl2 (0.19 g, 0.24 mmol), and 1M K2CO3 (˜3.5 mL). The flask was flushed with N2, capped, and heated to 95° C. The mixture was allowed to stir for 12 h at 95° C., cooled, and was diluted with EtOAc (100 mL) and water (20 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3×75 mL). The organic layers were combined and were washed with brine (1×50 mL). The organic layer was dried (NasSO4), filtered, and concentrated in vacuo to provide a crude maroon semisolid was placed under high vacuum. The crude material was purified using ISCO (120 g silica Gold column) using a gradient of 100% hexanes to 100% EtOAc (trace included). Fractions 31-55 were combined, concentrated in vacuo, and placed under high vacuum to provide 420 mg (50%) of compound 97 as an off-white solid.
To intermediate 97 (90 mg, 0.13 mmol) in CH2Cl2 (3 mL) under N2 was added TFA (1 mL) in one portion and the resultant solution was stirred under N2 at rt 1.5 hr. The mixture was concentrated to dryness and was treated with 4.0 M HCl/Dioxane (3 mL) for 30 min. The mixture was concentrated in vacuo and was placed in vacuo to provide 82 mg (99%) of the tetrahydrochloride salt of compound 98. LC-MS=505.2.
To a solution of the tetrachloride salt of compound 98 (82 mg, 0.13 mmol) in DMF (1.5 mL) at −15° C. (acetone/ice bath) was added Int-4e (58 mg, 0.27 mmol) followed by HATU (0.10 g, 0.27 mmol). The mixture was stirred or 15 minutes whereupon DIPEA (0.16 mL, 0.89 mmol) was added dropwise. This mixture was then stirred at −15° C. until the reaction was deemed to be complete by LCMS (˜90 min) The mixture was quenched by adding 3 mL H2O and 15 mL EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc (2×7 mL) and the organic layers were combined. The organic layer was washed with H2O (3×3 mL), brine (3×3 mL), and dried over anhydrous Na2SO4, filtered, and concentrated to provide ˜0.2 g of brown residue which was kept in vacuo for ˜1 hr. The crude material was purified using reverse-phase HPLC (Gilson) using a C18 column with a gradient: 0% ACN to 90% ACN/10% water (both with 0.1% TFA) to provide 0.12 g (97%) of compound 99 as its dihydrochloride salt after treatment with HCl. LC-MS (M+H)=903.5.
To a solution of compound 97 (0.16 g, 0.23 mmol) in DMF (2 mL) was added NCS (31 mg, 0.23 mmol) in a single portion. The mixture was heated to 50° C. and was allowed to stir for about 15 hours for 14 hours. The mixture was then cooled to room temperature and concentrated in vacuo to provide a brown semisolid residue, which was purified using ISCO using a 40 g column and a gradient of 100% hexanes to 100% EtOAc to provide 160 mg (87%) of 100 an off-white solid. LC-MS=739.2
To compound 100 (0.13 g, 0.17 mmol) in MeOH (1 mL) at rt was added 4N HCl in dioxane (0.5 mL) to provide a yellow, homogenous mixture. The resulting solution was allowed to stir for 2.5 hours. The mixture was concentrated in vacuo and the crude semisolid was triturated with Et2O (3×4 mL) to provide compound 101 (115 mg, 99%) as a light orange solid that was dried further under high vacuum and used without further purification. LC-MS (M+H)=539.1.
To a solution of compound 101 (115 mg, 0.17 mmol) in DMF (1.5 mL) at −10° C. (ice/acetone) was added compound Int-1a (62 mg, 0.35 mmol), HATU (0.13 g, 0.35 mmol), followed by dropwise addition of DIPEA (0.21 mL, 1.2 mmol) to provide an orange, homogenous solution. The resulting solution was allowed to stir for 2 h at −10° C. whereupon the reaction mixture was diluted with water (1.5 mL) and EtOAc (4 mL) The mixture was allowed to warm to rt and the layers were separated. The aqueous layer was extracted with EtOAc (3×4 mL) and the organic layers were combined. The organic layer was washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated in vacuo. The crude material by reverse-phase HPLC using a C18 column with a gradient of 10% ACN to 90% ACN/10% water (0.1% TFA) to provide 35 mg (22%) of compound 102 as a pale yellow dihydrochloride salt after treatment with HCl. LC-MS=937.5
Using the method described in Example 36, Step C, compound 101 (70 mg, 0.10 mmol) was reacted with compound Int-4e (47 mg, 0.21 mmol) to provide 90 mg (87%) of compound 103 as its dihydrochloride salt after HCl treatment. LC-MS: 973.5.
To a 0° C. solution of compound Int-38a (2 g, 8.80 mmol) in MeOH (10 mL) and ether (10 mL) was added trimethylsilyldiazomethane (8.80 mL, 17.60 mmol, 2 M solution in toluene) dropwise. Then resulting reaction was allowed to warm to room temperature and was allowed to stir for 14 hours. The reaction mixture was then concentrated in vacuo to provide compound Int-38b (2.1 g, 8.80 mmol, 100% yield) which was used without further purification.
To a −78° C. solution of compound Int-38b (0.5 g, 2.072 mmol) and chloroiodomethane (0.602 mL, 8.29 mmol) in THF (5 mL), was added LDA (5.18 mL, 10.36 mmol, 2 M solution in THF/heptane) dropwise. The reaction was allowed to stir for 10 minutes at −75° C., then a solution of added acetic acid (2 mL) in THF (10 mL) was added dropwise. The resulting reaction was allowed to stir for an additional 10 minutes at −78° C., then the reaction mixture was diluted with EtOAc (100 mL), washed sequentially with brine, NaHCO3 solution and water, then was dried over MgSO4, filtered and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel (EtOAc-Hexane) to provide compound Int-38c (230 mg, 0.886 mmol, 42.7% yield).
A solution of 4-bromobenzimidamide hydrochloride (163 mg, 0.693 mmol) and K2CO3 (192 mg, 1.386 mmol) in a mixture of THF (1 mL)/water (0.2 mL) was heated at 65° C. and allowed to stir at this temperature for 5 minutes. A solution of compound Int-38c (90 mg, 0.347 mmol) in THF (1 mL) was then added dropwise and the resulting reaction was allowed to stir for 14 hours at 65° C. The reaction mixture was then diluted with EtOAc (100 mL) and washed with water and brine. The organic layer was dried over MgSO4, filtered and concentrated in vacuo and the resulting residue was purified using flash column chromatography on silica gel (Silicagel 12 g, EtOAc/Hexane) to provide compound Int-38d (20 mg, 0.049 mmol, 14.28% yield).
Using the method described in Example 36, step A, compound Int-38d (79 mg, 0.20 mmol) was reacted with compound Int-38e (0.11 g, 0.22 mmol) to provide compound 104 (50 mg, 0.071 mmol, 55%).
Using the method described in Example 36, step C, compound 104 (20 mg, 0.021 mmol) was converted to compound 105 (12 mg. 0.011 mmol, 55%).
Compounds 106-109, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
Compound Int-39a (6 g, 24.09 mmol) in CH2Cl2 (80 mL) was treated dropwise with Br2 (1.253 mL, 24.33 mmol). The mixture was allowed to stir for about 15 hours then concentrated in vacuo. The residue obtained was recrystallized from THF to provide compound Int-39b, which was dried in vacuo (5.3 g; 67%).
Compound Int-39b (5.3 g, 16.16 mmol) and BOC-PRO-OH (3.65 g, 16.97 mmol) in Acetonitrile (50 mL) was cooled to 20° C. and DIPEA (3.39 mL, 19.39 mmol) was added dropwise. The mixture was allowed to warm to 25° C. and allowed to stir for 4 hours. The reaction was diluted with 100 mL ethyl acetate washed with 1×50 mL aq. 1 N HCl; 2×50 mL brine, filtered and the solvent was evaporated in vacuo. The material was recrystallized from ethyl acetate to provide compound Int-39c (4.8 g; 64%).
A solution of Int-39c (4.8 g, 10.38 mmol) in xylenes (25 mL) was treated with ammonium acetate (0.800 g, 10.38 mmol) and heated at 100° C. for 10 hours. The reaction was cooled and concentrated in vacuo. The crude residue was recrystallized from ethyl acetate to provide compound Int-39d (3.8 g; 83%).
An oven-dried resealable Schlenk tube was charged with compound Int-39d (200 mg, 0.452 mmol), bis(pinacolato)diboron (115 mg, 0.452 mmol), 1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) and potassium acetate (133 mg, 1.356 mmol). The tube was backfilled with nitrogen, and eioxane (5 mL) was added. The Schlenk tube was sealed and was heated to 90° C. for 2 hours. The reaction mixture, which contains compound Int-39e, was used directly in the next step.
The Schlenk tube containing the reaction mixture from Step 4 was cooled to room temperature and compound Int-25c (0.208 g, 0.452 mmol), 1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (0.033 g, 0.045 mmol) and K2CO3 (1.355 mL, 1.355 mmol) were added. The Schlenk tube was resealed, backfilled with nitrogen and heated to 90° C. for 4 hours. The reaction mixture was cooled to room temperature and filtered through a plug of SiO2. The filtrate was concentrated in vacuo and the resulting residue was purified using a 40 g RediSep Rf silica column (Teledyne Isco, Lincoln, Nebr., PN 69-2203-312) on a CombiFlash Rf 200 system (Teledyne Isco, PN 68-5230-006). A gradient of 0-5% CH3OH in CH2Cl2 was run. Detection was at 254 nm. The fractions that contained product were collected and concentrated in vacuo to provide compound 110 (0.17 g 50%).
Compound 110 (168 mg, 0.226 mmol) and TFA (3 mL) were stirred together at 25° C. for 4 hours. Excess TFA was removed in vacuo and the solid was dried in vacuo for 10 hours to provide compound 111, which was used without further purification.
Compound 111 (80 mg, 0.122 mmol) was dissolved in DMF (3 mL) and to the resulting solution was added compound Int-1a (46.9 mg, 0.268 mmol) and HATU (116 mg, 0.305 mmol). The reaction was cooled to −15° C. and DIPEA (0.064 mL, 0.365 mmol) was added. The reaction was then allowed to stir for 1 hour and allowed to warm to 0° C. and quenched with water. The solvent was removed in vacuo to provide a residue which was purified using reversed-phase HPLC (Gilson instrument using a gradient-type analytical system at a flow rate of 1.0 mL/min with a linear gradient 0-90% 1% TFA-acetonitrile-1% TFA water). The fractions containing product were combined and concentrated in vacuo and the solid product obtains was dried in vacuo for about 15 hours to provide compound 112 as a TFA salt (54 mg; 47%).
Compounds 113-118, depicted in the table below, were prepared using the methods described in the Example above and substituting the appropriate reactants and/or reagents.
Measurement of inhibition by compounds of the present invention was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or mutations were used. In addition, potency measurements were made using different formats of the replicon assay, including different ways of measurements and different plating formats. See Jan M. Vrolijk et al., A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C, 110 J. V
TaqMan®-Based Assay Protocol:
Compounds of the present invention were assayed for cell-based anti-HCV activity using the following protocol. Replicon cells were seeded at 5000 cells/well in 96-well collagen I-coated Nunc plates in the presence of the test compound. Various concentrations of test compound, typically in 10 serial 2-fold dilutions, were added to the assay mixture, with the starting concentration ranging from 250 μM to 1 μM. The final concentration of DMSO was 0.5%, fetal bovine serum was 5%, in the assay media. Cells were harvested on day 3 by the addition of 1× cell lysis buffer (Ambion cat #8721). The replicon RNA level was measured using real time PCR (TaqMan® assay). The amplicon was located in 5B. The PCR primers were: 5B.2F, ATGGACAGGCGCCCTGA (SEQ. ID NO. 1); 5B.2R, TTGATGGGCAGCTTGGTTTC (SEQ. ID NO. 2); the probe sequence was FAM-labeled CACGCCATGCGCTGCGG (SEQ. ID NO. 3). GAPDH RNA was used as endogenous control and was amplified in the same reaction as NS5B (multiplex PCR) using primers and VIC-labeled probe recommended by the manufacturer (PE Applied Biosystem). The real-time room temperature-PCR reactions were run on ABI PRISM 7900HT Sequence Detection System using the following program: 48° C. for 30 minutes, 95° C. for 10 minutes, 40 cycles of 95° C. for 15 sec, 60° C. for 1 minute. The ΔCT values (CT5B-CTGAPDH) were plotted against the concentration of test compound and fitted to the sigmoid dose-response model using XLfit4 (MDL). EC50 was defined as the concentration of inhibitor necessary to achieve ΔCT=1 over the projected baseline; EC90 the concentration necessary to achieve ΔCT=3.2 over the baseline. Alternatively, to quantitate the absolute amount of replicon RNA, a standard curve was established by including serially diluted T7 transcripts of replicon RNA in the Taqman assay. All TaqMan® reagents were from PE Applied Biosystems. Such an assay procedure was described in detail in e.g. Malcolm et al., Antimicrobial Agents and Chemotherapy 50: 1013-1020 (2006).
HCV replicon EC50 assay data for various replicons and mutants was calculated for selected compounds of the present invention using this method and is provided in the tables above herein. This data indicates that the compounds of the present invention are highly active versus a wide variety of HCV NS5A replicons and mutants.
The study of the HCV life cycle has been difficult due to the lack of a cell-culture system to support the HCV virus. To date, compounds in different structural classes acting on different sites within the HCV polyprotein have demonstrated efficacy in various species, including humans, in reducing HCV viral titers. Furthermore, the subgenomic replicon assay is highly correlated with efficacy in non-humans and humans infected with HCV. See K. del Carmen et al., Annals of Hepatology, 2004, 3:54.
It is accepted that the HCV replicon system described above is useful for the development and the evaluation of antiviral drugs. See Pietschmann, T. & Bartenschlager, R., Current Opinion in Drug Discovery Research 2001, 4:657-664).
The present invention is not to be limited by the specific embodiments disclosed in the examples that are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.
A number of references have been cited herein, the entire disclosures of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US12/54603 | 9/11/2012 | WO | 00 | 11/6/2014 |
